Document:

EX-10.10

 Exhibit 10.10 

AMENDED AND RESTATED INFORMATION SHARING AND COOPERATION AGREEMENT 

by and among 
 IMMUNOVANT SCIENCES
LTD. 
 AND 
 ROIVANT SCIENCES
LTD. 
 Dated as of December 28, 2018 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 ARTICLE 1 DEFINITIONS AND INTERPRETATION
	  	 	1	 
			
	 Section 1.01
	 	Definitions	  	 	1	 
	 Section 1.02
	 	Additional Defined Terms	  	 	5	 
	 Section 1.03
	 	Other Definitional and Interpretive Matters	  	 	6	 
		
	 ARTICLE 2 FINANCIAL REPORTING AND DISCLOSURE COVENANTS
	  	 	6	 
			
	 Section 2.01
	 	Financial Reporting and Controls	  	 	6	 
	 Section 2.02
	 	Private Company Information Rights	  	 	11	 
		
	 ARTICLE 3 COMPLIANCE COVENANTS
	  	 	11	 
			
	 Section 3.01
	 	Compliance	  	 	11	 
		
	 ARTICLE 4 EXCHANGE OF INFORMATION; CONFIDENTIALITY
	  	 	14	 
			
	 Section 4.01
	 	Privilege	  	 	14	 
	 Section 4.02
	 	Ownership of Information	  	 	14	 
	 Section 4.03
	 	Record Retention	  	 	14	 
	 Section 4.04
	 	Limitation of Liability	  	 	14	 
	 Section 4.05
	 	Confidentiality	  	 	15	 
	 Section 4.06
	 	Protective Arrangements	  	 	16	 
	 Section 4.07
	 	Preservation of Legal Privileges	  	 	16	 
		
	 ARTICLE 5 TAX MATTERS
	  	 	17	 
			
	 Section 5.01
	 	PFIC	  	 	17	 
	 Section 5.02
	 	QEF Information	  	 	17	 
		
	 ARTICLE 6 DISPUTE RESOLUTION
	  	 	17	 
			
	 Section 6.01
	 	Limitation on Monetary Damages Equitable Remedies	  	 	17	 
	 Section 6.02
	 	Disputes	  	 	18	 
	 Section 6.03
	 	Escalation; Mediation	  	 	18	 
	 Section 6.04
	 	Binding Arbitration	  	 	18	 
		
	 ARTICLE 7 FURTHER ASSURANCES
	  	 	19	 
			
	 Section 7.01
	 	Further Assurances	  	 	19	 
		
	 ARTICLE 8 MISCELLANEOUS
	  	 	20	 
			
	 Section 8.01
	 	General	  	 	20	 

  
 -i- 

							
	 Section 8.02
	 	Counterparts; Entire Agreement; Conflicting Agreements	  	 	20	 
	 Section 8.03
	 	No Construction Against Drafter	  	 	20	 
	 Section 8.04
	 	Governing law	  	 	20	 
	 Section 8.05
	 	Assignability	  	 	20	 
	 Section 8.06
	 	Notices	  	 	21	 
	 Section 8.07
	 	Severability	  	 	22	 
	 Section 8.08
	 	Force Majeure	  	 	22	 
	 Section 8.09
	 	Headings	  	 	22	 
	 Section 8.10
	 	Termination; Survival	  	 	22	 
	 Section 8.11
	 	Waivers of Default	  	 	22	 
	 Section 8.12
	 	Specific Performance	  	 	22	 
	 Section 8.13
	 	Amendments	  	 	23	 
	 Section 8.14
	 	Waiver of Jury Trial	  	 	23	 
	 Section 8.15
	 	Limitation on Monetary Damages	  	 	23	 
	 Section 8.16
	 	Indemnity and Expenses	  	 	23	 
	 Section 8.17
	 	Maintenance of Insurance	  	 	24	 
	 Section 8.18
	 	No Third-Party Beneficiaries	  	 	24	 
	 Section 8.19
	 	Expenses	  	 	24	 

  
 -ii- 

 AMENDED AND RESTATED INFORMATION SHARING AND COOPERATION AGREEMENT 

This AMENDED AND RESTATED INFORMATION SHARING AND COOPERATION AGREEMENT (this “Agreement”), dated as of December 28,
2018 (the “Effective Date”), is entered into by and among Immunovant Sciences Ltd., a Bermuda exempted limited company (the “Company”), Roivant Sciences Ltd., a Bermuda exempted limited company
(“Roivant”), and the Persons who from time to time become Shareholders of the Company in accordance with this Agreement and execute and deliver a Joinder Agreement, substantially as set forth on Exhibit A (a “Joinder
Agreement”), (with each of the Company, Roivant and such Persons, individually, a “Party” and together, the “Parties”). 

RECITALS 
 WHEREAS, Roivant is
the legal and beneficial owner of all of the issued and outstanding Common Shares of the Company; 
 WHEREAS, the Parties hereto entered
into that certain Information Sharing and Cooperation Agreement, effective as of August 20, 2018 (the “Original Shareholder’s Agreement”), pursuant to which the Parties entered into an agreement to provide for certain rights and
obligations associated with the Roivant’s ownership of Common Shares; 
 WHEREAS, the Parties hereto desire to amend and restate the
Original Shareholder’s Agreement in its entirety as set forth herein; and 
 WHEREAS, the Parties intend that this Agreement shall set
forth the principal arrangements between Roivant and the Company regarding the sharing of information and cooperation of the Parties in connection with the preparation of each Party’s financial statements and, to the extent applicable in the
future, their respective reporting obligations under other circumstances, from and after the date of effectiveness of its registration statement for an IPO (the “IPO Effective Date”); 

NOW, THEREFORE, in consideration of the covenants and agreements contained herein, the parties hereto agree as follows: 

ARTICLE 1 
 DEFINITIONS AND
INTERPRETATION 
 Section 1.01 Definitions. The following terms, as used herein, have the following meanings: 

“Affiliate” means, with respect to any Person, any other Person that, directly or indirectly through one or more
intermediaries, controls, is controlled by or is under common control with such Person, including any general partner, managing member, officer or director of such Person or any venture capital, private equity or other investment fund or account now
or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company or investment advisor with, such Person. 

 “Applicable Money Laundering Laws” means Laws applying to the Company and,
in the case of each Subsidiary of the Company, the Laws applying to such Subsidiary, prohibiting money laundering. 

“Board” means the Board of Directors of the Company. 

“Business Day” means any day other than a Saturday or Sunday on which banks are open for business in New York, New York,
London, United Kingdom, and Bermuda. 
 “Bye-laws” means the Amended and Restated Bye-laws of the Company, as the same may be amended from time to time. 
 “Common Shares”
means the common shares of the Company. 
 “Compliance Officer” means, with respect to any Person, the individual on the
senior management of such Person who has been delegated the responsibility for ensuring compliance with all Specified Laws. 

“Compliance Program” means a quality and regulatory compliance program, overseen by the Compliance Oversight Committee, for
ensuring compliance by the Company and its Subsidiaries with the Specified Laws. 
 “Control” means the possession,
directly or indirectly, of the power to direct or cause the direction of the management and policies of a person, whether through the ownership of voting securities, by contract or otherwise, with “Controlled” having a correlative meaning.

 “Data Privacy and Cybersecurity Rules and Regulations” means, collectively, all of the following to the extent relating
to data privacy, data protection or cybersecurity (including the collection, storage, use, maintenance, access, disclosure, processing, security, transfer, aggregation, confidentiality, integrity and availability) of Personal Information, and
confidential, proprietary and/or business information: (i) all Laws, encompassing U.S. state and federal, regional and international data privacy and cybersecurity laws, regulations and guidance including but not limited to the Health Insurance
Portability and Accountability Act, the Gramm-Leach-Bliley Act, the Federal Information Security Management Act, the Fair Credit Reporting Act, the Fair and Accurate Credit Transaction Act, the Federal Trade Commission Act, the Privacy Act of 1974,
the CAN-SPAM Act, the Telephone Consumer Protection Act, the Telemarketing and Consumer Fraud and Abuse Prevention Act, Children’s Online Privacy Protection Act, the EU Data Protection Directive, the EU
General Data Protection Regulation, the Canadian Personal Information Protection and Electronic Documents Act, the Swiss Federal Act on Data Protections, and U.S. state data privacy, cybersecurity and data breach notification laws, (ii) the
Company’s own rules, policies, procedures and public statements (including all data protection and privacy policies and related notices, (iii) industry-recognized privacy and cybersecurity standards (such as NAI, ISO 27001, COBIT, NIST,
HIPAA, PCI-DSS, ITAR, etc.), and (iv) contracts into which the Company has entered or by which it is otherwise bound. 

  
 -2- 

 “Equity Securities” means, without duplication, (a) the Common Shares,
(b) any other class of equity security or equity-linked security issued by the Company or any corporate successor thereto and (c) any other securities convertible into or exchangeable or exercisable for, or options, warrants or other
rights to acquire, Common Shares, or any other equity or equity-linked securities issued by the Company or any corporate successor thereto. Schedule A sets forth the names of, and the number of Equity Securities owned by each Shareholder as
of the date hereof, and the Company shall update Schedule A from time to time to reflect any issuances or transfers of Equity Securities that occur. 

“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated from
time to time thereunder. 
 “FCPA” means the U.S. Foreign Corrupt Practices Act of 1977, as amended. 

“FDA” means the U.S. Food and Drug Administration. 

“GAAP” means United States generally accepted accounting principles. 

“Government Official” means (a) an officer or employee of any national, regional, local or other component of
government, (b) a director, officer or employee of any entity in which a government or any component of a government possesses a majority or controlling interest; (c) a candidate for public office; (d) a political party or political
party official; (e) an officer or employee of a public international organization (e.g., the European Commission or World Bank); and (f) any individual who is acting in an official capacity for any government, component of a government,
political party or public international organization, even if such individual is acting in that capacity temporarily and without compensation. 

“Health-Related Requirements” means (a) the federal Laws applicable to the activities of a pharmaceutical or biological
product manufacturer, including but not limited to federal health care program and FDA requirements relating to research; development; interactions with health care professionals, patient advocacy or assistance organizations, charitable
organizations, and professional societies; data integrity and security; labeling; marketing; sale; distribution; import; export; product pricing and reimbursement; Quality Management Systems; price, safety, and other reporting obligations; safety
monitoring; or exclusion and debarment (collectively, “manufacturer activities”); (b) the U.S. anti-corruption Laws (e.g., the FCPA) applicable to manufacturer activities occurring outside the United States; and (c) non-U.S. Laws that are equivalent to the requirements set forth in clauses (a) and (b) of this definition (e.g., the UKBA and any other applicable Laws prohibiting bribery and corruption). 

“IPO” means an underwritten initial public offering of Equity Securities of the Company or any corporate successor thereto
(it being understood that an IPO shall not include a registration effected solely to implement an employee benefit plan, a merger or other business combination or a registration on Form S-4, Form S-8 or any substantially equivalent or successor form thereto). 
 “Laws” means any
national, federal, state, provincial, local or foreign law, statute, code, ordinance, rule, regulation, order, judgment, writ, stipulation, award, injunction, decree or arbitration award or finding. 

“Local ABAC Laws” means local Laws applying to the Company and, in the case of each Subsidiary of the Company, the Laws
applying to such Subsidiary, prohibiting bribery and corruption. 

  
 -3- 

 “Person” means an individual, company, corporation, limited liability
company, partnership, association, joint stock company, trust, joint venture, unincorporated organization or other entity or organization, including a governmental authority. 

“Quality Management Systems” means those systems supporting the development and manufacture of pharmaceutical drug substances
(i.e., active pharmaceutical ingredients (APIs)) and drug products, including biotechnology and biological products, throughout the product lifecycle. 

“Regulatory and Governance Requirements” means all (a) ethics, conduct, conflict, insider trading and other internal
policies and guidelines applicable generally to any Qualified Shareholder or any of their respective Representatives and (b) applicable regulatory, internal controls (including internal controls with respect to financial reporting and
remediation of any deficiencies), audit, compliance, record keeping, document retention, financial reporting, tax and legal requirements applicable to any Qualified Shareholder or any of its respective Representatives, in each case, as amended or
updated from time to time. 
 “Reportable Event” means any event that may (a) represent a substantial deviation from
applicable policies, procedures, systems or controls regarding Specified Laws; or (b) represent a violation of any Specified Law that could have a material compliance, regulatory, legal financial, reputational or safety impact on the Company,
its Affiliates, and its or their stakeholders or patients, in each case, as reasonably determined by the Company. 

“Representatives” means, with respect to a Person, such Person’s directors, officers, employees, agents, legal counsel,
financial advisors and other representatives, including any appointed representative of such Person serving on the Board. 

“Sanctions” means economic or financial sanctions or trade embargoes, including (a) United Nations sanctions imposed
pursuant to any United Nations Security Council Resolution; (b) U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury, the U.S. Department of State, the U.S. Department of Commerce or any
other U.S. government authority or department; (c) EU restrictive measures implemented pursuant to any EU Council or Commission Regulation or Decision adopted pursuant to a Common Position in furtherance of the EU’s Common Foreign and
Security Policy; (d) UK sanctions adopted by the Terrorist Asset-Freezing etc. Act 2010 or other legislation and statutory instruments enacted pursuant to the United Nations Act 1946 or the European Communities Act 1972 or enacted by or
pursuant to other Laws; and (e) any other trade, economic or financial sanctions Laws, embargoes or restrictive measures administered, enacted or enforced by any authority, government or official institution as applicable to Company and each of
its Subsidiaries or any transaction in which Company or each Subsidiary of the Company is engaged. 
 “Sarbanes-Oxley Act”
means the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated from time to time thereunder. 

“SEC” means the U.S. Securities and Exchange Commission. 

“Securities Act” means the U.S. Securities Act of 1933, as amended, and the rules and regulations promulgated from time to
time thereunder. 

  
 -4- 

 “Shareholders” means Roivant and each of the Persons who from time to time
become Shareholders of the Company and a party to this Agreement by executing and delivering a Joinder Agreement hereto. 

“Specified Laws” means (a) the UKBA or FCPA; (b) applicable trade, economic or financial sanctions Laws, embargoes
or other restrictive measures, including (i) Local ABAC Laws, (ii) Applicable Money Laundering Laws, (iii) Sanctions and (iv) applicable Laws prohibiting fraud, tax evasion, insider dealing and market manipulation;
(c) applicable Health-Related Requirements; (d) applicable securities Laws, including the Exchange Act, the Sarbanes-Oxley Act and the Securities Act; and (e) applicable Data Privacy and Cybersecurity Rules and Regulations
(f) all other Laws of any jurisdiction that are similar to the Laws described in the foregoing clauses (a) – (e). 

“Subsidiary” means, with respect to any specified Person, any other Person (a) Controlled by such first Person or
(b) of which at least a majority of the securities or ownership interests having by their terms ordinary voting power to elect a majority of the board of directors or other persons performing similar functions is directly or indirectly owned or
controlled by such first Person and/or by one or more of its Subsidiaries. 
 “Trigger Date” has the meaning set forth in
the Bye-laws. 
 “UKBA” means the UK Bribery Act 2010, as amended. 

Section 1.02 Additional Defined Terms. Each of the following terms is defined in the Section set forth opposite such term: 

 

			
	 TERM
	  	 SECTION

	 Agreement
	  	Preamble
	 Annual Financial Statements
	  	2.01(c)
	 Effective Date
	  	Preamble
	 Company
	  	Preamble
	 Compliance Oversight Committee
	  	3.01(b)
	 Escalation Notice
	  	6.03(a)
	 Expert Councils
	  	3.01(e)
	 Indemnified Liabilities
	  	8.16(a)(i)
	 Indemnitees
	  	8.16(a)(i)
	 IPO Effective Date
	  	Recitals
	 Joinder Agreement
	  	Preamble
	 PFIC
	  	5.01
	 Policies
	  	3.01(a)
	 Privilege
	  	4.01
	 Providing Party
	  	4.05(a)
	 Quarterly Financial Statements
	  	2.01(b)(i)
	 Roivant
	  	Preamble
	 Roivant Public Filings
	  	2.01(g)
	 Receiving Party
	  	4.05(a)

  
 -5- 

 Section 1.03 Other Definitional and Interpretive Matters. Unless otherwise
expressly provided herein, for purposes of this Agreement, the following rules of interpretation shall apply: 
 (a) Calculation of
Time. When calculating the period before which, within which or after which any act is to be done or step taken pursuant to this Agreement, the date that is the reference date in calculating such period shall be excluded. If the last day of such
period is not a Business Day, the period in question shall end on the next succeeding Business Day. 
 (b) Dollars. Any reference in
this Agreement to “$” means U.S. dollars. 
 (c) Annexes/Exhibits/Schedules. The Annexes, Exhibits and Schedule to this
Agreement are hereby incorporated and made a part hereof and are an integral part of this Agreement. Any capitalized terms used in any Annex, Exhibit or Schedule but not otherwise defined therein shall be defined as set forth in this Agreement. 

(d) Gender and Number. Any reference in this Agreement to gender shall include all genders, and words imparting the singular number only
shall include the plural and vice versa. 
 (e) Herein. The words “herein,” “hereof” and “hereunder”
refer to this Agreement as a whole and not merely to a subdivision in which such words appear unless the context otherwise requires. 
 (f)
Other. The words “include,” “includes” and “including” when used herein shall be deemed in each case to be followed by the words “without limitation.” The word “extent” in the phrase “to
the extent” means the degree to which a subject or other thing extends, and such phrase does not mean simply “if.” 
 ARTICLE
2 
 FINANCIAL REPORTING AND DISCLOSURE COVENANTS 

Section 2.01 Financial Reporting and Controls(a) . The Parties agree that they will comply with the requirements set forth in this
Section 2.01, (A) with respect to Sections 2.01 (d), (e), (h), (i), (j), (k), (l), (m) and (n) from and after the Effective Date, and (B) with respect to Sections 2.01(a), (b), (c), (f), and (g),
from and after the IPO Effective Date and such time that Roivant (i) notifies the Company that it is actively engaging in the preparation of a registration statement to be filed under the Securities Act for an initial public offering of its
securities or (ii) has a class of securities registered under Section 13(a) or 15(d) of the Exchange Act and Roivant is required (x) by GAAP to consolidate the results of operations and financial position of the Company, (y) to
account for its investment in the Company under the equity method of accounting (determined in accordance with GAAP and consistent with SEC reporting requirements) or (z) to otherwise include separate financial statements of the Company in its
filings with the SEC pursuant to any rule of the SEC. 

  
 -6- 

 (a) Disclosure of Financial Controls. In connection with the filing of Roivant’s
annual and quarterly reports under the Exchange Act or any investigations of prior periods, the Company shall cause its principal executive officer and principal financial officer to provide to Roivant and its Representatives (A) on a timely
basis, if this provision is applicable by virtue of Section 2.01(B)(ii)(x) and (B) on a timely basis and if reasonably requested by Roivant, if this provision is applicable by virtue of Sections 2.01(B)(i) or
(ii)(y) or (z), (1) certifications to Roivant corresponding to those required under Sections 302 and 906 of the Sarbanes-Oxley Act, (2) any certificate that may be reasonably necessary for Roivant to satisfy the requirements applicable to
it under Section 404 of the Sarbanes-Oxley Act, (3) any certificates or other written information that the Company’s principal executive officer or principal financial officer received as support for the certificates provided to
Roivant and (4) a reasonable opportunity to discuss with the Company’s principal financial officer and other appropriate officers and employees of the Company any issues reasonably related to the foregoing. 

(b) Quarterly Financial Statements. 

(i) As soon as reasonably practicable and no later than 15 days before the date by which Roivant is required to file a
quarterly report on Form 10-Q if this provision is applicable by virtue of Section 2.01(B)(ii)(x) above or 10 days before the date by which Roivant is required to file a quarterly
report on Form 10-Q if this provision is applicable by virtue of Section 2.01(B)(i) or (ii)(y) or (z) above, the Company will deliver to Roivant and its
Representatives reasonably complete drafts of (A) the consolidated financial statements of the Company (and notes thereto) for the quarterly periods and for the period from the beginning of the current fiscal year to the end of such quarter,
setting forth in each case in comparative form for each such fiscal quarter of the Company the consolidated figures (and notes thereto) for the corresponding quarter and periods of the previous fiscal year prepared in accordance with Article 10 of
Regulation S-X and GAAP and (B) a discussion and analysis by management of the Company’s financial condition and results of operations for such fiscal period, including, without limitation, an
explanation of any material period-to-period change and any off-balance sheet transactions, prepared in accordance with
Item 303(b) of Regulation S-K. The information set forth in (A) and (B) above is referred to in this Agreement as the “Quarterly Financial Statements”. As soon as reasonably possible
and no later than 5 days before the date by which Roivant is required to file a quarterly report on Form 10-Q, the Company will deliver to Roivant and its Representatives the final form of the Quarterly
Financial Statements; provided, however, that the Company may continue to revise such Quarterly Financial Statements prior to its filing thereof in order to make corrections, updates and changes, which corrections, updates and changes,
if substantive, will be delivered by the Company to Roivant as soon as reasonably possible. At Roivant’s request, the Company’s Representatives will consult and discuss with Roivant’s Representatives any such corrections, updates and
changes. To the extent that the fiscal year of Roivant is not the same as the fiscal year of the Company or Roivant is not subject to reporting obligations under Section 13(a) or 15(d) of the Exchange Act, the obligation to deliver Quarterly
Financial Statements before the date by which Roivant is required to file its quarterly report on Form 10-Q shall be determined based on the date by which the Company is required to file its quarterly report
on Form 10-Q. 
 (ii) As soon as reasonably practicable and no later than 45 days
after the end of its fiscal year, the Company will deliver to Roivant and its Representatives its consolidated financial statements (and notes thereto) for the last quarter of its fiscal year, setting forth in each case in comparative form for such
fiscal quarter of the Company the consolidated 

  
 -7- 

 
figures (and notes thereto) for the corresponding quarter of the previous fiscal year prepared in accordance with Article 10 of Regulation S-X and GAAP;
provided, however, that the Company may continue to revise such financial statements in order to make corrections, updates and changes in connection with the preparation of its audited annual financial statements, which corrections,
updates and changes, if substantive, will be delivered by the Company to Roivant as soon as reasonably possible. 
 (c) Annual Financial
Statements. As soon as reasonably practicable and no later than 45 days after the end of its fiscal year if this provision is applicable by virtue of Section 2.01(B)(ii)(x) above or 55 days after the end of its fiscal
year if this provision is applicable by virtue of Section 2.01(B)(i) or (ii)(y) or (z) above, the Company will deliver to Roivant and its Representatives reasonably complete drafts of (i) the consolidated
financial statements of the Company (and notes thereto) for such year, setting forth in each case in comparative form the consolidated figures (and notes thereto) for the previous fiscal years, prepared in accordance with Article 10 of Regulation S-X and GAAP and (ii) a discussion and analysis by management of the Company’s financial condition and results of operations for such year, including, without limitation, an explanation of any material period-to-period changes and any off-balance sheet transactions, prepared in accordance with Item 303(a) and 305 of Regulation S-K. The information set forth in (i) and (ii) above is referred to in this Agreement as the “Annual Financial Statements”. As soon as reasonably possible and no later than 15 days before the
date by which Roivant is required to file its annual report on Form 10-K if this provision is applicable by virtue of Section 2.01(B)(ii)(x) above or 10 days before the date by which
Roivant is required to file its annual report on Form 10-K if this provision is applicable by virtue of Section 2.01(B)(ii)(y) or (z) above, the Company will deliver to Roivant
and its Representatives the final form of the Annual Financial Statements and an opinion on the Annual Financial Statements by the Company’s independent registered public accountants (the “Company Auditors”); provided,
however, that the Company may, if necessary, continue to revise such Annual Financial Statements prior to the filing thereof in order to make corrections, updates and changes, which corrections, updates and changes, if substantive, will be
delivered by the Company to Roivant as soon as reasonably possible. At Roivant’s request, the Company’s Representatives will consult and discuss with Roivant’s Representatives any such corrections, updates and changes. To the extent
that the fiscal year of Roivant is not the same as the fiscal year of the Company or Roivant is not subject to reporting obligations under Section 13(a) or 15(d) of the Exchange Act, the obligation to deliver Annual Financial Statements before
the date by which Roivant is required to file its annual report on Form 10-K shall be determined based on the date by which the Company is required to file its quarterly report on Form 10-K. 
 (d) Supplemental Information. Roivant may reasonably request, and within a reasonable
period of time agreed to by Roivant and the Company following such request, the Company shall, at Roivant’s sole cost and expense, make available to Roivant and its Representatives other supplemental information on a monthly, quarterly or
annual basis necessary or advisable in order to satisfy Roivant’s financial reporting requirements pursuant to 2.01(B)(ii) above, and other Regulatory and Governance Requirements, the form, substance and timing of such supplemental information
to be agreed by Roivant and the Company in advance. 

  
 -8- 

 (e) Conformance of Financial Statements. Subject to the other terms in this
Agreement, the Company shall not make or adopt any significant changes to its accounting estimates or accounting policies and principles from those in effect on the Effective Date to the extent that such changes would significantly impact
Roivant’s financial statements. Notwithstanding the previous sentence, nothing in this Agreement shall prevent the Company making those changes to its accounting estimates or accounting policies and principles if such changes are required by
GAAP or which the audit committee of the Company determines are necessary or appropriate for the proper presentation of the Company’s financial statements; provided, however, that the Company shall first consult with Roivant. 

(f) Press Releases and Similar Information. The Company and Roivant will consult with each other as to the timing of their annual and
quarterly earnings releases and any interim financial guidance for a current or future period and, to the extent reasonably possible. If the Company and Roivant are unable to agree as to such timing, then Roivant and the Company shall each make
reasonable efforts to issue their respective annual and quarterly earnings releases at approximately the same time on the same date, which will include for these purposes during the same period of time beginning after the close of market on one day
and ending just prior to the opening of market on the next day. Roivant and the Company agree to consult with each other as to the timing of their respective earnings release conference calls. 

(g) Cooperation on Filings. The Company agrees to provide to Roivant and its Representatives, and to instruct the Company Auditors to
provide to Roivant and its Representatives, all material information with respect to the Company that Roivant reasonably requires in connection with the preparation by Roivant of its Quarterly Reports on
Form 10-Q, Annual Reports to shareholders, Annual Reports on Form 10-K, any Current Reports on Form 8-K and any
registration statements, or other filings made by Roivant with the SEC, any national securities exchange or otherwise made publicly available with respect to the disclosures pertaining to the Company (collectively, the “Roivant Public
Filings”). The Company and Roivant agree to reasonably cooperate with each other with respect to the requesting and furnishing of such required information in order to enable Roivant to file all Roivant Public Filings within the deadlines
as required by applicable law. The Company will cause the Company Auditors (as defined below) to consent to any reference to them as experts in any Roivant Public Filings required under any law, rule or regulation. In addition, Roivant shall
provide to the Company necessary and appropriate information that the Company reasonably requires, to the extent Roivant has such information and the Company does not, in connection with required filings made by the Company to a reasonably
applicable governmental authority. 
 (h) Access to the Company Auditors. The Company will authorize the Company Auditors to make
reasonably available to Roivant’s auditors both the personnel who performed, or are performing, the annual audit and quarterly reviews of the Company and work papers related to the annual audit and quarterly reviews of the Company, in all cases
within a reasonable time prior to Roivant’s auditors opinion date, so that Roivant’s auditors are able to perform the procedures they consider necessary to take responsibility for the work of the Company Auditors as it relates to
Roivant’s auditors report on Roivant’s statements. 
 (i) Access to Records. If Roivant determines in good faith that there
may be a material inaccuracy in the Company’s financial statements or deficiency or inadequacy in the Company’s internal accounting controls or operations that could reasonably be expected to materially impact Roivant’s financial
statements, and at Roivant’s request, the Company will provide Roivant’s internal auditors with reasonable access to the Company’s books and records so that Roivant may conduct reasonable audits relating to the financial statements
provided by the Company under this Agreement, as well as to the internal accounting controls and operations of the Company. 

  
 -9- 

 (j) Tax Information. Each Party shall make available to the other and its
Representatives all information relating to such Party or any of its Subsidiaries necessary or appropriate to enable the other Party to prepare its federal, state, local and foreign income tax returns; provided that Roivant and its
Representatives shall have no obligation to provide information about (A) its directors or investors or (B) its Subsidiaries other than the Company and the Company’s subsidiaries. Such information shall be prepared by the Party making
it available at its sole cost and expense, and each Party shall make such information available to the other Party and its Representatives with reasonable promptness in light of the timing applicable to the purpose for which such information is to
be used. 
 (k) Compliance Inspection Rights. Without limiting the generality of the requirements of clause (m) of this
Section 2.01, the Company shall provide Roivant and its Representatives with the right to visit and inspect any of the offices and properties of the Company and its Subsidiaries and inspect the books and records of the
Company and its Subsidiaries and controlled Affiliates as they relate to Specified Laws, as well as to review and make copies of correspondence and other documents, however sent or received, possessed by the Company and/or the Company’s
Subsidiaries and controlled Affiliates pertaining to compliance with the Policies and Specified Laws, at such times as a Reportable Event has been communicated to the Board for the purpose of verifying and evaluating the Company’s and its
Subsidiaries’ compliance with the Company’s Compliance Program, and to make appropriate officers and directors of the Company and its Subsidiaries available at such times as reasonably requested by Roivant for consultation with Roivant and
its Representatives with respect to matters relating to the Compliance Program. 
 (l) Information Rights. The Company shall, and
shall cause each of its Subsidiaries to, promptly, upon reasonable request, (A) make available to Roivant and its Representatives such information, documents and other materials, whether current, historical or prospective, relating to the
business of Company or any of its Subsidiaries and in its possession and control (and subject to any Third Party confidentiality and use obligations) as Roivant may from time to time reasonably request, subject at all times to applicable law
regarding the disclosure of any such information; and (B) give Roivant and its Representatives (x) the right to examine and make copies of or extracts from any records of the Company or any of its Subsidiaries for any reasonable purpose,
(y) reasonable access to the Company’s and its Subsidiaries’ offices, properties, and employees, and (z) the reasonable opportunity to discuss any matters with the Company’s and its Subsidiaries’ senior management, in
the case of each of clauses (A) and (B) in connection with any proper purpose. For the avoidance of doubt, proper purpose includes use by Roivant of any such information, data, documents or other materials for its own internal research
purposes, including but not limited to, for purposes of analyzing, and/or deriving learnings from, clinical data provided by the Company to Roivant hereunder; provided that, except for such use rights, in no event does the provision of information
hereunder grant Roivant any other rights or licenses under or to any of the Company’s intellectual property, compounds, products or programs. 

  
 -10- 

 (m) Provision of Information. The Company shall provide, or cause to be provided, to
Roivant, as soon as reasonably practicable after request therefor, confirmation as to whether the Company is in possession of information that would reasonably be considered to be material nonpublic information with respect to the Company under
applicable U.S. securities laws, and sufficient additional information as is necessary, in the reasonable judgment of Roivant and its counsel, to determine whether such information is material with respect to Roivant under applicable U.S. securities
laws. 
 (n) Fiscal Year. The Company shall not change its fiscal year without the prior written consent of Roivant. 

Section 2.02 Private Company Information Rights. If the Company is not subject to the requirements of
Section 2.01 (a), (b), (c), (f), and (g), then the Company shall make available to Roivant: 
  

	 	i.	 consolidated annual financial statements, audited by an accounting firm of international standing and
reputation, as soon as practicable, and in any event within 75 Business Days after the end of each fiscal year; 

  

	 	ii.	 unaudited consolidated quarterly financial statements, as soon as practicable, and in any event within 40
Business Days after the end of each fiscal quarter; 

  

	 	iii.	 unaudited monthly detailed statements of cash balances of each Subsidiary of the Company, as soon as
practicable, and in any event, within 40 Business Days after the end of each month; 

  

	 	iv.	 an annual budget, as soon as practicable, and in any event at least 60 Business Days prior to the beginning of
a fiscal year; 

  

	 	v.	 the Company’s, and each of its Subsidiaries’, capitalization table from time to time, and in any
event at least once quarterly within 15 Business Days after the end of each fiscal quarter; 

  

	 	vi.	 an updated long-term business plan annually, as soon as practicable, and in any event within 15 Business Days
after the end of each fiscal year. 

 Notwithstanding the foregoing, documents required to be delivered under
Section 2.02(i) and (ii), to the extent any such documents are included in materials otherwise filed with the SEC shall be deemed to have been delivered on the date on which the Company files such documents with the SEC and such
documents are publicly available on the SEC’s EDGAR filing system or any successor thereto. 
 ARTICLE 3 

COMPLIANCE COVENANTS 

Section 3.01 Compliance. The Company shall observe the following requirements: 

(a) Adoption of Policies. The Company shall adopt, implement and maintain at all times policies with respect to the Specified Laws as
Roivant may from time to time direct, including with respect to regulatory, Quality Management Systems standards, internal controls 

  
 -11- 

 
(including with respect to financial reporting and remediation of deficiencies), audit, compliance, record keeping, document retention, financial reporting, tax and legal requirements
(collectively, the “Policies”), that, in each case, are (x) applicable to the Company and its Subsidiaries and its and their respective Representatives, (y) consistent with, and no less restrictive than, the corresponding
policies established by Roivant, as they may be updated from time to time, and (z) are otherwise satisfactory to Roivant. For the avoidance of doubt, to the extent that Roivant has not established a corresponding policy with respect to a
requirement that the Company wishes to establish, which the Company must confirm with Roivant, the Company’s Policy will govern unless and until Roivant establishes a corresponding policy. After such time, the Company’s Policy may continue
to govern only if it is no less restrictive than Roivant’s policy. In establishing its corresponding policies, Roivant shall in good faith consider any timely and reasonable requests or inputs from the Company. The Company shall provide Roivant
with a copy of each of its Policies upon finalization and shall promptly notify the Company of any updates, amendments or changes thereto. 

(b) Compliance Committee. Absent a waiver by Roivant, the Board shall at all times have a Compliance Oversight Committee (the
“Compliance Oversight Committee”), whose composition, meetings and proceedings shall be subject to the requirements for any other committee of the Board pursuant to the Bye-laws, to oversee
the Company’s and its Subsidiaries’ Compliance Program. In administering the Compliance Program, the Compliance Oversight Committee shall: 

(i) appoint a Compliance Officer who will be responsible for the management and administration of the Compliance Program;
provided that, until the Compliance Oversight Committee shall have appointed a Compliance Officer, the principal executive officer of the Company shall perform the duties of the Compliance Officer; 

(ii) cause the Company and its Subsidiaries to implement a training and education plan to ensure that the Company’s
employees receive adequate training regarding the Compliance Program; and 
 (iii) cause the Company to establish an internal
reporting procedure that includes a confidential hot line mechanism to enable directors, officers, employees and agents of the Company and its Subsidiaries to report to the Compliance Officer (and/or such other person who is not in the reporting
individual’s chain of command as the Compliance Oversight Committee may from time to time designate) any identified issues or questions associated with the Company’s policies, conduct, practices or procedures related to the Specified Laws.

 (c) Compliance Officer. In administering the Compliance Program, the Compliance Officer shall: 

(i) make periodic reports (but in any event at least quarterly) regarding the status of the Compliance Program directly to the
Compliance Oversight Committee; 
 (ii) make reports regarding compliance matters directly to the Board at any time he or she
considers appropriate; 

  
 -12- 

 (iii) annually certify to the Compliance Oversight Committee (together with
the principal executive officer of the Company, if the principal executive officer is not acting as Compliance Officer) that to the best of his or her knowledge and after reasonable due diligence, except as otherwise described in the report, the
Company and its Subsidiaries and their respective directors, officers, employees and agents are each in compliance with all Specified Laws applicable to the Company and its Affiliates; provided that, if either the Compliance Officer or the
principal executive officer of the Company is unable to provide such a certification, he or she shall provide an explanation directly to the Compliance Oversight Committee of the reasons why he or she is unable to provide such certification; and

 (iv) notify the Compliance Oversight Committee of (1) any actual or threatened investigation, regulatory or legal
proceeding involving the Specified Laws or (2) any Reportable Event, in each case within 48 hours after discovery of the underlying facts or as soon thereafter as practicable. 

(d) Compliance with Laws. 

(i) The Company shall not, and shall cause its Subsidiaries and its and their respective directors, officers, employees and
agents not to, directly or indirectly, make, offer, promise or authorize any payment or transfer of any money or anything of value to or for the benefit of a Government Official or individual employed by another entity in the private sector that
would violate either the UKBA or the FCPA or engage in any conduct that would reasonably be expected to be deemed to violate the UKBA or the FCPA in any material respect. 

(ii) The Company shall not, and shall cause its Subsidiaries and its and their respective directors, officers and employees not
to, directly or indirectly, make, offer, promise or authorize any payment or transfer of any money or anything of value to or for the benefit of a Government Official or individual employed by another entity in the private sector that would violate
Local ABAC Laws or engage in any conduct that would reasonably be expected to be deemed to violate Local ABAC Laws, Applicable Money Laundering Laws, Sanctions or applicable Laws prohibiting fraud, tax evasion, insider dealing and market
manipulation in any material respect. 
 (iii) The Company shall, and shall cause each of its direct and indirect
Subsidiaries to, keep and maintain books and records reflecting accurately and in reasonable detail transactions involving the Company and its direct and indirect Subsidiaries and to implement financial controls giving reasonable assurance that
payments will be made by or on behalf of the Company and its direct and indirect Subsidiaries only in accordance with management instructions. 

(iv) The Company shall, and shall cause its Subsidiaries and its and their respective directors, officers and employees to,
otherwise comply in all material respects with all Specified Laws. 

  
 -13- 

 (e) Participation on Expert Councils. To facilitate collaboration and best practices
amongst Roivant, the Company and other Affiliates of Roivant and the Company, Roivant may from time to time sponsor expert councils (the “Expert Councils”). The Company shall participate in such Expert Councils by appointing an
individual with relevant expertise to each such Expert Council. No such Expert Council shall be convened on more than a semi-annual basis, unless urgent circumstances dictate otherwise. The objectives of the Expert Councils shall include
facilitating discussion on changes in the applicable field of expertise, trends in the field and experiences, best practices and issues of a general nature. All proceedings of an Expert Council shall be subject to the terms of confidentiality set
forth in Article 4. 
 ARTICLE 4 

EXCHANGE OF INFORMATION; CONFIDENTIALITY 

Section 4.01 Privilege. In the event that a Party reasonably determines that the provision of information pursuant to this
Agreement would violate any law or bona fide contractual restriction, or result in the waiver of any Privilege, the Parties shall take all commercially reasonable measures to permit the compliance with the provision of information obligations in a
manner that avoids any such harm or consequence, which shall include, but not be limited to, compliance with Sections 4.05, 4.06 and 4.07 hereof. For purposes of this Agreement, the term “Privilege” shall mean
information and advice that has been previously developed but is legally protected from disclosure under legal privileges, such as the attorney-client privilege, work product exemption or similar concept of legal protection 

Section 4.02 Ownership of Information. Any information owned by a Party that is provided to the other Party pursuant to the terms
of this Agreement shall be deemed to remain the property of such Party. Unless expressly set forth in this Agreement, nothing contained in this Agreement shall be construed as granting or conferring any right, title or interest (whether by license
or otherwise) in, to, or under any such information. 
 Section 4.03 Record Retention. To facilitate the provision of
information pursuant to this Agreement, the Company agrees to retain all information in its possession or control in accordance with its document retention policies, as such policies may be reasonably amended or revised after the Effective Date. The
Company shall provide Roivant with reasonable notice of any material amendment or revision to its retention policies after the Effective Date. The Company shall not materially amend or revise its retention policy in effect at the time of its IPO for
a period of three years after the IPO. 
 Section 4.04 Limitation of Liability. Each Party shall have no liability to the other
Party in the event that any information exchanged or provided pursuant to this Agreement is found to be inaccurate or the requested information is not provided, in the absence of willful misconduct by, or gross negligence of, such Party. Each Party
shall not have any liability to the other Party if any information is destroyed in compliance with its document retention policies. 

  
 -14- 

 Section 4.05 Confidentiality. 

(a) Subject to Section 4.07, each Party (the “Receiving Party”) agrees to hold, and to cause its
Representatives, including for the avoidance of doubt underwriters or other parties providing financing to such Party, to hold in strict confidence, with at least the same degree of care that applies to its confidential and proprietary information
pursuant to its policies in effect as of the Effective Date, all information with respect to the other Party (the “Providing Party”) that is accessible to it, in its possession (including information in its possession prior to the
Effective Date) or furnished by the Providing Party or its Representative, or accessible to, in the possession of, or furnished to the Receiving Party or its Representatives pursuant to this Agreement or otherwise, including as a result of the
Receiving Party’s Representatives serving on the Board, except, in each case, to the extent that such information (i) is or becomes part of the public domain through no breach of this Agreement by the Receiving Party or its
Representatives, (ii) was independently developed following the Effective Date by the Receiving Party or its Representatives who have not accessed or otherwise received the applicable information; provided that such independent
development can be demonstrated by competent, contemporaneous written records of the Receiving Party, or (iii) became or becomes available to the Receiving Party following the Effective Date on a
non-confidential basis from a third Party who is not bound directly or indirectly by a duty of confidentiality to the Providing Party. The Parties acknowledge that they may have in their possession
confidential or proprietary information of third Parties that was received under confidentiality or non-disclosure agreements with such third Party. The Parties will hold in strict confidence the confidential
and proprietary information of third Parties to which they have access in accordance with the terms of any such agreements. 
 (b)
Notwithstanding anything herein to the contrary, Roivant and its Representatives shall be permitted to: 
 (i) use the
Company’s trademark in its written materials when referencing the Company; 
 (ii) disclose confidential information
(x) to Roivant’s attorneys, accountants, consultants and other professionals who are subject to a duty or undertaking of confidentiality to the extent necessary to obtain their services in connection with monitoring its investment in the
Company or enforcing any of its rights under this Agreement or any other agreements with the Company; (y) to any Affiliate, partner, member, prospective member, or wholly-owned subsidiary of Roivant; provided that Roivant informs such
person that such information is confidential and such person is under an obligation to maintain the confidentiality of such information and to use such information in a manner consistent with the proper purpose for which the information has been
shared with Roivant or its Representatives; and (z) to any investor or potential investor of Roivant, if such prospective purchaser agrees to be bound by confidentiality provisions at least as restrictive as this
Section 4.05 and also agrees to customary standstill agreement with respect to the Company’s securities until such time as such confidential information is publicly disclosed; 

  
 -15- 

 (iii) provide confidential information regarding the Company (including but
not limited to historical financial and other information) to persons who have a legitimate reason to know such information and who are under an obligation to keep such information confidential and to use such information in a manner consistent with
the proper purpose for which the information has been shared with Roivant or its Representatives; and 
 (iv) publish non-confidential information of the Company (including but not limited to historical financial and other information). 

(c) Notwithstanding anything to the contrary in this Article 4, the Receiving Party shall have no right to use any
information disclosed by the Providing Party unless otherwise provided for in this Agreement or specifically provided for in any other agreement between the Parties. 

Section 4.06 Protective Arrangements. In the event that the Receiving Party either determines on the advice of its counsel that it
is required to disclose any information pursuant to applicable Law (including the rules and regulations of the SEC in connection with any proposed registration of the Receiving Party’s securities under the Securities Act, or pursuant to the
requirements of any national securities exchange) or receives any request or demand from any governmental or regulatory authority to disclose or provide information of the Providing Party that is subject to the confidentiality provisions hereof, the
Receiving Party shall, to the extent permitted by Law and except in connection with a general regulatory examination unrelated to the Providing Party, notify the Providing Party prior to disclosing or providing such information and shall reasonably
cooperate at the expense of the Receiving Party in seeking any reasonable protective arrangements (including by seeking confidential treatment of such information) requested by the Providing Party. Subject to the foregoing, the Receiving Party may
thereafter disclose or provide information to the extent required by such Law or requested or required by such governmental authority; provided, however, that the Receiving Party provides the Providing Party, to the extent legally
permissible and except in connection with a general regulatory examination unrelated to the Providing Party, upon request with a copy of the information so disclosed. 

Section 4.07 Preservation of Legal Privileges. 

(a) The Parties recognize that they possess and will possess Privileged information. Each Party recognizes that they shall be jointly entitled
to the Privilege with respect to such Privileged information and that each shall be entitled to maintain, preserve and assert for its own benefit all such information and advice, but the Parties shall ensure that such information is maintained so as
to protect the Privileges with respect to the other Party’s interest. To that end, no Party will knowingly waive or compromise any Privilege associated with such information and advice without the prior written consent of the other Party, which
shall not be unreasonably withheld. In the event that Privileged information is required to be disclosed to any arbitrator or mediator in connection with a dispute between the Parties, such disclosure shall not be deemed a waiver of Privilege with
respect to such information, and any Party receiving it in connection with a proceeding shall be informed of its nature and shall be required to safeguard and protect it. 

(b) Upon receipt by either Party of any subpoena, discovery or other request that may call for the production or disclosure of information that
is the subject of a Privilege, or if a Party obtains knowledge that any current or former employee of a Party has received any subpoena, discovery or other request that may call for the production or disclosure of such information, such Party shall
provide the other Party a reasonable opportunity to review the information and to assert 

  
 -16- 

 
any rights it may have under this Section 4.07 or otherwise to prevent the production or disclosure of such information. Absent receipt of written consent from the other
Party to the production or disclosure of information that may be covered by a Privilege, each Party agrees that it will not produce or disclose any information that may be covered by a Privilege unless a court of competent jurisdiction has entered a
final, nonappealable order finding that the information is not entitled to protection under any applicable Privilege. 
 ARTICLE 5 

TAX MATTERS 

Section 5.01 PFIC. For so long as Roivant owns Equity Securities, the Company will use reasonable best efforts to avoid, in
respect of any taxable year, being treated as a passive foreign investment company (“PFIC”) within the meaning of Section 1297 of the Code, including, but not limited to, causing any of its subsidiaries to file an election
pursuant to Treasury Regulation Section 301.7701-3. No later than 75 days after the end of each taxable year, the Company shall deliver to Roivant an analysis as to whether the Company believes that it
will be treated as a PFIC in respect of such taxable year. Such analysis may be prepared by the Company, but in preparing such analysis the Company shall consult with its internationally recognized tax advisors. 

Section 5.02 QEF Information. For so long as Roivant owns Equity Securities, the Company shall use reasonable best efforts to
provide, and shall cause each of its subsidiaries to use reasonable best efforts to provide, to Roivant all information that may be necessary to allow Roivant, and any direct or indirect owners of Roivant, to evaluate the analysis referenced in
Section 5.01 and to fulfill their U.S. tax filing and reporting obligations. The Company shall provide, and shall cause each of its subsidiaries to provide, such information to Roivant, and any direct or indirect owners of
Roivant, as may reasonably be required to timely file and maintain a “qualified electing fund” election (as defined in Section 1295(a) of the Code) with respect to any such entity. 

ARTICLE 6 
 DISPUTE RESOLUTION

 Section 6.01 Limitation on Monetary Damages Equitable Remedies. Subject to Section 8.16, the
Company and Roivant hereby agree that neither Party shall have any liability for monetary damages for any breach of this Agreement so long as such Party used commercially reasonable efforts to comply with the obligation such Party breached and
continues thereafter to use commercially reasonable efforts to remedy such breach. In addition to other remedies provided by applicable law, the Company and Roivant may each enforce the provisions of this Agreement through such legal or equitable
remedies as a court of competent jurisdiction shall allow without the necessity of proving actual damages or bad faith, and the Party subject to a claim under this Agreement hereby waives any claim or defense that such Party has an adequate remedy
at law, and waives any requirement for the securing or posting of any bond in connection with such equitable remedy. 

  
 -17- 

 Section 6.02 Disputes. The procedures for discussion, negotiation and
mediation set forth in this Article 6 shall apply to all disputes, controversies or claims (whether arising in contract, tort or otherwise) that may arise out of or relate to, or arise under or in connection with, this Agreement or the
transactions contemplated hereby or thereby (including all actions taken in furtherance of the transactions contemplated hereby on the Effective Date). the Company hereby agrees that its members of the Board or senior management that are not
affiliated with Roivant shall lead all discussions, negotiations and mediations that occur pursuant to this Article 6. 

Section 6.03 Escalation; Mediation. 

(a) It is the intent of the Parties to use their respective commercially reasonable efforts to resolve expeditiously any dispute, controversy
or claim between or among them with respect to the matters covered by this Agreement. In furtherance of the foregoing, any Party involved in a dispute, controversy or claim with respect to such matters may deliver a notice (an “Escalation
Notice”) demanding an in person meeting involving representatives of the Parties at a senior level of management of the Parties (or if the Parties agree, of the appropriate strategic business unit or division within such entity). A copy of
any such Escalation Notice shall be given to the general counsel, or like officer or official, of each Party involved in the dispute, controversy or claim (which copy shall state that it is an Escalation Notice pursuant to this Agreement). Any
agenda, location or procedures for such discussions or negotiations between the Parties may be established by the Parties from time to time; provided, however, that the Parties shall use their commercially reasonable efforts to meet
within 30 days of the Escalation Notice. 
 (b) If the Parties are not able to resolve the dispute, controversy or claim through the
escalation process referred to in clause (a) above within 90 days of delivery of the Escalation Notice, then the matter shall be referred to mediation; provided that such period of time may be extended upon mutual written consent of the
Parties. The Parties shall retain a mediator to aid the Parties in their discussions and negotiations by informally providing advice to the Parties. Any opinion expressed by the mediator shall be strictly advisory and shall not be binding on the
Parties, nor shall any opinion expressed by the mediator be admissible in any other proceeding. The mediator may be chosen from a list of mediators previously selected by the Parties or by other agreement of the Parties. Costs of the mediation shall
be borne equally by the Parties involved in the matter, except that each Party shall be responsible for its own expenses. Mediation shall be a prerequisite to the commencement of any action by either Party. 

Section 6.04 Binding Arbitration. 

(a) If, after complying with the provisions set forth in Section 6.03 above the Parties are unable to reach
resolution to any dispute, controversy or claim between the Parties, any such dispute, controversy or claim between the Parties, including any claim arising out of, in connection with, or in relation to the interpretation, performance, breach, or
termination of this Agreement, shall be resolved exclusively and finally by confidential binding arbitration. The seat, or legal place, of arbitration shall be New York, New York. The language of the arbitration shall be English. The
arbitration shall be administered by the International Centre for Dispute Resolution in accordance with its International Arbitration Rules in force when the Notice of Arbitration is submitted in accordance with such Rules. Each Party shall
select one person to act as arbitrator and the two selected shall select a third arbitrator, who shall act as president of the panel. Where there are multiple claimants or multiple respondents, the multiple claimants, jointly, and the multiple
respondents, jointly, shall select the party-appointed arbitrators. Except as may be 

  
 -18- 

 
required by law, to comply with a legal duty, or to pursue a legal right, neither a party nor an arbitrator may disclose the existence, content, or results of any arbitration hereunder without
the prior written consent of both parties. Nothing herein shall prevent either Party from seeking provisional measures from any court of competent jurisdiction, and any such request shall not be deemed incompatible with the agreement to
arbitrate or a waiver of the right to arbitrate. Each Party shall consent, for purposes of provisional measures or the enforcement of any arbitral award, to the non-exclusive jurisdiction of the state and
federal courts located in New York, New York, and each Party shall not assert that such courts constitute forum non-conveniens. The award shall be final and binding on the parties. Judgment on the award may be entered in any court of
competent jurisdiction.
 (b) Unless otherwise agreed in writing, the Parties will continue to provide service and honor all other
commitments under this Agreement during the course of dispute resolution pursuant to the provisions of this Article 6, except to the extent such commitments are the subject of such dispute, controversy or claim. 

ARTICLE 7 
 FURTHER ASSURANCES

 Section 7.01 Further Assurances. 

(a) In addition to the actions specifically provided for elsewhere in this Agreement, each of the Parties hereto will cooperate with each other
and shall use their commercially reasonable efforts to take, or cause to be taken, all actions, and to do, or cause to be done, all things, reasonably necessary, proper or advisable under applicable laws, regulations and agreements to consummate and
make effective the transactions contemplated by this Agreement. 
 (b) Without limiting the foregoing each Party hereto shall cooperate with
the other Party, and without any further consideration, but at the expense of the requesting Party, to execute and deliver, or use its commercially reasonable efforts to cause to be executed and delivered, all instruments, including instruments of
conveyance, assignment and transfer and to make all filings with, and to obtain all consents, approvals or authorizations of, any governmental authority or any other person or entity under any permit, license, agreement, indenture, order, decree,
financial assurance (including letter of credit) or other instrument, and to take all such other actions as such Party may reasonably be requested to take by such other Party hereto from time to time, consistent with the terms of this Agreement.

 (c) Nothing in this Agreement shall be construed to restrict or limit any right, responsibility or authority of either of Parties hereto
or their respective, independent registered public accountants, audit committee or board of directors in violation of any law, legal requirement or listing standard applicable to such Party, whether existing today or hereafter. In the event either
Party hereto reasonably determines that any provision in this Agreement does or will so limit any right, responsibility or authority of such Party or such Party’s independent registered public accountants, audit committee or board of directors,
then the Parties hereto agree to attempt to negotiate in good faith any changes necessary or advisable to this Agreement to avoid or prevent such violation. 

  
 -19- 

 ARTICLE 8 

MISCELLANEOUS 

Section 8.01 General. For the avoidance of doubt, nothing in this Agreement, shall limit the ability of Roivant to exercise any
rights to which it is entitled under applicable law or otherwise by virtue of its ownership of the Equity Securities of the Company, including any and all rights with respect to the access to, and use of, information or assets of the Company. 

Section 8.02 Counterparts; Entire Agreement; Conflicting Agreements. 

(a) This Agreement may be executed in one or more counterparts all of which shall be considered one and the same agreement, and shall become
effective when one or more counterparts have been signed by each of the Parties and delivered to the other Party. Execution of this Agreement or any other documents pursuant to this Agreement by facsimile or other electronic transmission (including
in PDF form) shall be deemed to be, and shall have the same effect as, executed by an original signature. 
 (b) This Agreement contains the
entire agreement of the Parties with respect to the subject matter hereof, supersede all previous agreements, negotiations, discussions, writings, understandings, commitments and conversations with respect to such subject matter and there are no
agreements or understandings between the Parties with respect to such subject matter other than those set forth or referred to herein or therein. 

(c) In the event and to the extent that there shall be a conflict between the provisions of this Agreement and the provisions of any other
agreement between the Parties, the other agreement shall control with respect to the subject matter thereof, and this Agreement shall control with respect to all other matters. 

Section 8.03 No Construction Against Drafter. The Parties acknowledge that this Agreement and all the terms and
conditions herein have been fully reviewed and negotiated by the Parties and their respective attorneys. Having acknowledged the foregoing, the Parties agree that any principle of construction or rule of law that provides that, in the event of
any inconsistency or ambiguity, an agreement shall be construed against the drafter of the agreement shall have no application to the terms and conditions of this Agreement. 

Section 8.04 Governing law. This Agreement shall be governed by and construed and interpreted in accordance with the laws of the
State of New York, without regard to the conflict of laws principles thereof that would result in the application of any law other than the laws of the State of New York. 

Section 8.05 Assignability. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective
heirs, successors, legal representatives and permitted assigns; provided, however, that no Party may assign its respective rights or delegate its respective obligations under this Agreement without the express prior written consent of the other
Party. 

  
 -20- 

 Section 8.06 Notices. All notices, requests, claims, demands and other
communications required or permitted hereunder to be given to a party to this Agreement shall be in person or in writing transmitted via email or mailed by registered or certified mail, postage prepaid, or otherwise delivered by hand or by
messenger, addressed to such party’s address as set forth below or at such other address as the party shall have furnished to each other party in writing in accordance with this provision. 

If to Roivant, to: 
 Roivant
Sciences Ltd. 
 Suite 1, 3rd Floor 

11-12 St. James’s Square 

London SW1Y 4LB, United Kingdom 

Attention: Corporate Secretary 

Email: info@roivant.com 
 with a
copy sent concurrently to: 
 Roivant Sciences, Inc. 

320 West 37th Street, 6th Floor 

New York, NY 10018 
 Attention:
General Counsel 
 If to the Company to: 

Immunovant Sciences Ltd. 
 Suite
1, 3rd Floor 
 11-12 St. James’s Square 

London SW1Y 4LB, United Kingdom 

Attention: Corporate Secretary 

with a copy sent concurrently to: 

Immunovant, Inc. 
 320 West 37th
Street, 6th Floor 
 New York, NY 10018 

Attention: Legal 
 Any notice
sent in accordance with this Section 8.06 shall be effective (i) if mailed, 7 Business Days after mailing, (ii) if sent by messenger, upon delivery, and (iii) if sent via facsimile or email, upon transmission
and electronic confirmation of receipt or (if transmitted and received on a non-Business Day) on the first Business Day following transmission and electronic confirmation of receipt (provided,
however, that any notice of change of address shall only be valid upon receipt). 

  
 -21- 

 Section 8.07 Severability. If any provision of this Agreement or the application
thereof to any person or circumstance is determined by a court of competent jurisdiction to be invalid, void or unenforceable, the remaining provisions hereof or the application of such provision to persons or circumstances or in jurisdictions other
than those as to which it has been held invalid or unenforceable, shall remain in full force and effect and shall in no way be affected, impaired or invalidated thereby, so long as the economic or legal substance of the transactions contemplated
hereby is not affected in any manner adverse to any Party. Upon such determination, the Parties shall negotiate in good faith in an effort to agree upon such a suitable and equitable provision to effect the original intent of the Parties. 

Section 8.08 Force Majeure. No Party shall be deemed in default of this Agreement to the extent that any delay or failure in the
performance of its obligations under this Agreement results from any cause beyond its reasonable control and without its fault or negligence, such as acts of God, acts of civil or military authority, embargoes, epidemics, war, riots, insurrections,
fires, explosions, earthquakes, floods, unusually severe weather conditions or labor problems. In the event of any such excused delay, the time for performance shall be extended for a period equal to the time lost by reason of the delay. 

Section 8.09 Headings. The article, section and paragraph headings contained in this Agreement are for reference purposes only and
shall not affect in any way the meaning or interpretation of this Agreement. 
 Section 8.10 Termination; Survival. This
Agreement and all covenants and obligations herein shall terminate upon the later of (a) the Trigger Date and (b) such time as Roivant is no longer required by GAAP reporting requirements to consolidate the results of operations and
financial position of the Company, account for its investment in the Company under the equity method of accounting (determined in accordance with GAAP and consistent with SEC reporting requirements) or otherwise include separate financial statements
of the Company in its filings with the SEC pursuant to any rule of the SEC; provided that (i) the Parties may terminate this Agreement at any time upon mutual written consent and (ii) Roivant may terminate this Agreement upon written
notice to the Company in the event of a bankruptcy, liquidation, dissolution or winding-up of the Company. Notwithstanding any termination of this Agreement pursuant to this
Section 8.10, the obligations of the Parties hereto pursuant to Sections 4.01, 4.02, 4.04, 4.05, 4.06, 4.07, Article 6, Article 7 and this Article 8 (other than Section 8.17 (Maintenance
of Insurance)) shall survive until the expiration of the applicable statute of limitations. 
 Section 8.11 Waivers of Default.
Waiver by any Party of any default by the other Party of any provision of this Agreement shall not be deemed a waiver by the waiving Party of any subsequent or other default, nor shall it prejudice the rights of the other Party. 

Section 8.12 Specific Performance. The Parties acknowledge that money damages may not be an adequate remedy for violations of this
Agreement .In the event of any actual or threatened default in, or breach of, any of the terms, conditions and provisions of this Agreement, the Party or Parties who are or are to be thereby aggrieved shall have the right to specific performance and
injunctive or other equitable relief of its rights under this Agreement, in addition to any and all other rights and remedies at law or in equity, and all such rights and remedies shall be cumulative. 

  
 -22- 

 Section 8.13 Amendments. No provisions of this Agreement shall be deemed waived,
amended, supplemented or modified by any Party, unless such waiver, amendment, supplement or modification is in writing and signed by an authorized representative of the Party against whom it is sought to enforce such waiver, amendment, supplement
or modification. 
 Section 8.14 Waiver of Jury Trial. SUBJECT TO ARTICLE 6 AND SECTIONS 8.10 AND 8.11 HEREIN,
EACH OF THE PARTIES HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY COURT PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF AND PERMITTED UNDER OR IN CONNECTION WITH THIS
AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH OF THE PARTIES HEREBY (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE
EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, AS APPLICABLE, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS
AND CERTIFICATIONS IN THIS SECTION 8.14. 
 Section 8.15 Limitation on Monetary Damages. The Parties hereto hereby agree
that no Party shall have any liability for monetary damages for any breach of this Agreement so long as such Party used commercially reasonable efforts to comply with the obligation such Party breached and continues thereafter to use commercially
reasonable efforts to remedy such breach. 
 Section 8.16 Indemnity and Expenses. 

(a) Indemnity. 

(i) The Company shall indemnify and hold harmless Roivant and its respective partners, shareholders, members, Affiliates,
directors, officers, fiduciaries, managers, controlling Persons, employees, agents, counsel and other representatives and each of the partners, shareholders, members, Affiliates, directors, officers, fiduciaries, managers, controlling Persons,
employees, agents, counsel and other representatives of each of the foregoing (collectively, the “Indemnitees”) from and against any and all actions, causes of action, suits, claims, liabilities, losses, damages and costs and out-of-pocket expenses in connection therewith (including reasonable attorneys’ and accountants’ fees and expenses) incurred by the Indemnitees or any of them on or
after the Effective Date (collectively, the “Indemnified Liabilities”) as a result of, arising out of or in any way relating to (i) Roivant’s status as a holder of Equity Securities and (ii) the operations of the
Company or any of its Subsidiaries; provided that the foregoing indemnification rights shall not be available with respect to any such Indemnified Liabilities arising on account of an Indemnitee’s gross negligence or willful misconduct;
provided, further, that, if and to the extent that the foregoing undertaking may be unavailable or unenforceable for any reason, the Company shall make the maximum contribution to the payment and satisfaction of each of the Indemnified
Liabilities which is permissible under applicable Law. 

  
 -23- 

 (ii) Each Party shall indemnify and hold harmless the other Party and its
Indemnitees for any breach of Section 4.05 hereof due to the gross negligence or willful misconduct of such Party or its Representatives. 

Section 8.17 Maintenance of Insurance. The Company shall, and shall cause its Subsidiaries to, (a) maintain Roivant as
additional named insured on each of its and its Subsidiaries’ insurance policies and arrangements during the term of this Agreement and (b) maintain insurance coverage reasonably sufficient to meet its indemnification obligations under
this Agreement. 
 Section 8.18 No Third-Party Beneficiaries. This Agreement is not intended, nor shall it be deemed, to confer
any rights or remedies on any person other than the Parties hereto and their respective successors and assigns. This Agreement does not create any third-party beneficiary hereto and the Company and Roivant are the only parties entitled to commence
any action, proceeding or claim under this Agreement. 
 Section 8.19 Expenses. Each Party is responsible for its own fees,
costs and expenses incurred in connection with this Agreement and the activities contemplated hereby; provided, further, to the extent that the observation of the covenants and performance of the obligations set forth in Article
2 result in additional significant financial expenses to the Company, upon the Company’s request, the Parties will discuss potential reimbursement by Roivant with respect to such additional financial expenses incurred by the Company. 

[Signature Pages Follow] 

  
 -24- 

 IN WITNESS WHEREOF, the parties hereto, intending to be legally bound, have caused this
Agreement to be executed as of the date first written above. 
  

			
	IMMUNOVANT SCIENCES LTD.
		
	By:	 	 /s/ Marianne Romeo

	Name: Marianne Romeo
	
	ROIVANT SCIENCES LTD.
		
	By:	 	/s/ Marianne Romeo
	Name: Marianne RomeoEX-10.11

 Exhibit 10.11 

EXECUTION VERSION 

EMPLOYMENT AGREEMENT 

This Employment Agreement (this “Agreement”) is entered into as of May 30, 2019, by and between Pete Salzmann
(the “Executive”) and Immunovant, Inc. (the “Company”). 
 RECITALS

 A. The Company desires the association and services of the Executive and the Executive’s skills, abilities, background
and knowledge, and is willing to engage the Executive’s services on the terms and conditions set forth in this Agreement. 
 B.
The Executive desires to be in the employ of the Company, and is willing to accept such employment on the terms and conditions set forth in this Agreement. 

C. This Agreement supersedes any and all prior and contemporaneous oral or written employment agreements or arrangements between the
Executive and the Company or any predecessor thereof. 
 AGREEMENT 

In consideration of the foregoing, the parties agree as follows: 

1. EMPLOYMENT BY THE COMPANY. 

1.1 Position; Duties. Subject to the terms and conditions of this Agreement, the Executive shall hold the position of Chief Executive
Officer of the Company. In this position, the Executive will have the duties and authorities normally associated with a Chief Executive Officer of a company. The Executive will report to the Board of Directors of the Company (the
“Board”). The Executive shall devote the Executive’s full business energies, interest, abilities and productive time to the proper and efficient performance of the Executive’s duties under this Agreement. 

1.2 Location of Employment. The Executive’s principal place of employment shall initially be the Company’s offices located in
New York, New York. The Executive understands that the Executive’s duties may require periodic business travel. 
 1.3 Start Date.
The Executive’s employment with the Company shall commence on or before June 4, 2019 (the “Start Date”).  

1.4 Exclusive Employment; Agreement not to Compete. Except with the prior written consent of the Board, the Executive will not, during
the Executive’s employment with the Company, undertake or engage in any other employment, occupation or business enterprise. During the Executive’s employment, the Executive agrees not to acquire, assume or participate in, directly or
indirectly, any position, investment or interest known by the Executive 

 EXECUTION VERSION 

 
 to be adverse or antagonistic to the Company, its business, or prospects, financial or
otherwise, or in any company, person, or entity that is, directly or indirectly, in competition with the business of the Company. Ownership by the Executive in professionally managed funds over which the Executive does not have control or discretion
in investment decisions, or, an investment of less than two percent (2%) of the outstanding shares of capital stock of any corporation with one or more classes of its capital stock listed on a national securities exchange or publicly traded on a
national securities exchange or in the over-the-counter market shall not constitute a breach of this Section. 

2. COMPENSATION AND BENEFITS. 

2.1 Salary and Signing Bonus. 

(a) The Company shall pay the Executive a base salary at the annualized rate of FOUR HUNDRED FIFTY THOUSAND dollars ($450,000) (the
“Base Salary”), less payroll deductions and all required withholdings, payable in regular periodic payments in accordance with the Company’s normal payroll practices. The Base Salary shall be prorated for any partial
year of employment on the basis of a 365-day year. The Base Salary shall be subject to periodic review and may be adjusted from time to time in the Board’s discretion. 

(b) The Executive will be eligible for a one-time signing bonus of FIVE HUNDRED THOUSAND
dollars ($500,000), payable on December 31, 2019 (the “Signing Bonus”), less payroll deductions and all required withholdings. If the Executive resigns from employment with the Company without Good Reason or the Company
terminates the Executive’s employment for Cause, in each case prior to the first anniversary of the Start Date, the Executive must repay the Signing Bonus in full to the Company within thirty (30) days of the effective date of termination.

 2.2 Annual Performance Bonus. Each fiscal year, the Executive will be eligible to earn an annual discretionary cash bonus (the
“Annual Performance Bonus”) with a target bonus opportunity equal to FIFTY percent (50%) of the Executive’s Base Salary, which could increase for outperformance of Company goals, based on the Board’s (and/or a
committee thereof) assessment of the Executive’s individual performance and overall Company performance. In order to earn and receive the Annual Performance Bonus, the Executive must remain employed by the Company through and including the date
on which the Annual Performance Bonus is paid. The Annual Performance Bonus, if any, will be paid no later than thirty (30) days following the end of the Company’s fiscal year (March 31st), or by April 30th. The Annual Performance Bonus
payable, if any, shall be prorated for the initial year of employment (on the basis of a three hundred sixty-five (365)-day year) and shall be prorated if the Company’s review or assessment of the
Executive’s performance covers a period that is less than a full fiscal year. 

 EXECUTION VERSION 

 
 2.3 Equity. 

(a) Subject to the terms of the Parent’s 2018 Equity Incentive Plan (the “Plan”) and approval of the grant
by the board of directors of the Parent (the “Parent Board”), the Executive will be granted an award of an option to purchase common shares of the Parent equal to THREE AND ONE-HALF
percent (3.5%) of the fully diluted common equity of the Parent (the “Option Award”). The Option Award will be granted on or around the twentieth (20th) day of the month following the Executive’s Start Date, with an
exercise price equal to the fair market value of Parent’s common shares on such date of grant, as set forth in the Plan, and will be subject to a four (4) year vesting period, with (i) twenty-five percent (25%) of the Option Award
vesting on the one-year anniversary of the Start Date and (ii) the balance of the Option Award vesting in a series of twelve (12) successive equal quarterly installments measured from the first (1st)
anniversary of the Start Date, provided the Executive is employed by the Company on each such vesting date. The Option Award will be governed by the Plan and other documents issued in connection with the grant. 

(b) The Executive may be eligible to receive additional discretionary annual equity incentive grants in amounts and on terms and
conditions determined by the Board in its sole discretion. 
 2.4 Benefits and Insurance. The Executive shall, in accordance with
Company policy and the terms of the applicable plan documents, be eligible to participate in benefits under any benefit plan or arrangement that may be in effect from time to time and made available to similarly situated Company executives
(including, but not limited to, being named as an officer for purposes of the Company’s Directors & Officers insurance policy). The Company reserves the right in its sole discretion to modify, add or eliminate benefits at any time. All
benefits shall be subject to the terms and conditions of the applicable plan documents, which may be amended or terminated at any time. The Executive shall be entitled to vacation each year, in addition to sick leave and observed holidays in
accordance with the policies and practices of the Company. Vacation may be taken at such times and intervals as the Executive shall determine, subject to the business needs of the Company. 

2.5 Expense Reimbursements. The Company will reimburse the Executive for all reasonable and documented business expenses that the
Executive incurs in conducting the Executive’s duties hereunder, pursuant to the Company’s usual expense reimbursement policies. 

2.6 Relocation Reimbursements. Subject to the terms of the Company’s travel and relocation policies, the Executive will be eligible
to receive relocation reimbursements for actual costs incurred in the Executive’s relocation, subject to a maximum reimbursement of $75,000 in actual costs incurred. Any relocation reimbursement shall be subject to a gross-up for applicable taxes (exclusive of the $75,000 cap). If the Executive resigns from employment with the Company without Good Reason or the Company terminates the Executive’s employment for Cause, in
each case on or prior to the first anniversary of the Start Date, the Executive must repay the relocation reimbursement in full to the Company. If any repayment is due to the Company pursuant to this Section, the Executive agrees that the amount of
the repayment due is payable in 

 EXECUTION VERSION 

 
 full immediately and the Executive agrees to permit the Company to deduct this amount
from any monies or benefits due to the Executive including wages, bonuses, reimbursements and/or expenses and any remaining amounts are the Executive’s responsibility. 

3. AT-WILL EMPLOYMENT. 

The Executive’s employment relationship with the Company is, and shall at all times remain,
at-will. This means that either the Executive or the Company may terminate the employment relationship at any time, for any reason or for no reason, with or without Cause (as defined below) or advance notice.

 4. PROPRIETARY INFORMATION OBLIGATIONS. 

As a condition of employment, the Executive agrees to execute and abide by the Company’s Employee
Non-Disclosure, Invention Assignment and Restrictive Covenant Agreement (“NDIA”). 

5. TERMINATION OF EMPLOYMENT. 

5.1 Termination Generally. Upon termination of Executive’s employment for any reason, the Company shall pay the Executive any
earned but unpaid Base Salary and unused vacation accrued (if applicable) through the date of termination, at the rates then in effect, less standard deductions and withholdings. The Company shall thereafter have no further obligations to the
Executive, except as set forth in this Section 5 or otherwise as required by law. 
 5.2 Termination Without Cause or Resignation for
Good Reason. If (i) the Company terminates Executive’s employment without Cause or the Executive resigns for Good Reason, (ii) the Executive furnishes to the Company an executed waiver and release of claims in the form
substantially similar to that attached hereto as Exhibit A, with any changes that the Company determines are necessary to comply with applicable law (the “Release”), which Release is
non-revocable prior to the Release Date (as defined below), and (iii) the Executive allows the Release to become effective in accordance with its terms, then the Executive shall receive an aggregate
amount equal to: (a) twelve (12) months of the Executive’s then current Base Salary and (b) twelve (12) months of COBRA coverage, with such aggregate amount payable in equal installments over the twelve (12) month period
following the date of the Executive’s termination in accordance with customary payroll practices, but no less frequently than monthly. Such payments shall commence within the next payroll cycle following the Release Date and will be subject to
required withholding, provided that if such period spans two calendar years, payment shall not commence until the later taxable year, and provided further that any amounts that would have otherwise been paid during the period between the
Executive’s termination date and the first payment date in accordance with payroll practices will be included in the first payment. 

5.3 Termination Without Cause Or Resignation For Good Reason Within Twelve Months Following Change In Control. If (i) the Company
terminates the Executive’s employment without Cause or the Executive resigns for Good Reason within twelve (12) months 

 EXECUTION VERSION 

 
 following a Change in Control (as defined in the Plan), (ii) the Executive furnishes to
the Company a Release, which Release is non-revocable prior to the Release Date , and (iii) the Executive allows the Release to become effective in accordance with its terms, then the Executive shall
receive an aggregate amount equal to: (a) one and a half (1.5) times the sum of the Executive’s then-current Base Salary and target Annual Performance Bonus (such Annual Performance Bonus to be calculated at fifty percent (50%) of the then
current Base Salary) for the year in which the termination takes place; and (b) eighteen (18) months of COBRA coverage, with such aggregate amount payable in equal installments over the eighteen (18) month period following the date of the
Executive’s termination in accordance with customary payroll practices, but no less frequently than monthly; and (c) any and all time-vested equity awards shall immediately vest in full. Such payments shall commence within the next payroll
cycle following the Release Date and will be subject to required withholding, provided that if such period spans two calendar years, payment shall not commence until the later taxable year, and provided further that any amounts that would have
otherwise been paid during the period between the Executive’s termination date and the first payment date in accordance with payroll practices will be included in the first payment. 

5.4 Definitions. For purposes of this Agreement, the following terms shall have the following meanings: 

(a) “Cause” shall mean the occurrence of any of the following, the Executive’s: (i) arrest
for, arraignment on, conviction of, or plea of no contest to, any felony or any crime involving moral turpitude or dishonesty; (ii) participation in a fraud against the Company; (iii) willful and material breach of the Executive’s
duties and obligations under this Agreement or any other agreement between the Executive and the Company or its affiliates that has not been cured (if curable) within thirty (30) days after receiving written notice from the Board of such
breach; (iv) engagement in conduct that causes or is reasonably likely to cause material damage to the Company’s property or reputation; (v) material failure to comply with the Company’s Code of Conduct or other material
policies; or (vi) violation of any law, rule or regulation (collectively, “Law”) relating in any way to the business or activities of the Company or its subsidiaries or affiliates, or other Law that is violated during
the course of the Executive’s performance of services hereunder that results in the Executive’s arrest, censure, or regulatory suspension or disqualification, including, without limitation, the Generic Drug Enforcement Act of 1992, 21
U.S.C. § 335(a), or any similar legislation applicable in the United States or in any other country where the Company intends to develop its activities. 

(b) “Good Reason” shall mean the occurrence of any of the following events without the Executive’s
consent: (i) a material reduction of the Executive’s Base Salary as initially set forth herein or as the same may be increased from time to time, provided, however, that if such reduction occurs in connection with a
Company-wide decrease in executive officer team compensation, such reduction shall not constitute Good Reason provided that it is a reduction of a proportionally like amount or percentage affecting the entire executive team not to exceed ten percent
(10%); or (ii) material reduction in the Executive’s authority, duties or responsibilities, as compared to the Executive’s authority, duties or responsibilities immediately prior to such reduction; provided, however, any
resignation by the Executive shall only be deemed 

 EXECUTION VERSION 

 
 for Good Reason pursuant to this definition if: (1) the Executive gives the Company
written notice of the Executive’s intent to terminate for Good Reason within thirty (30) days following the first occurrence of the condition(s) that the Executive believes constitute(s) Good Reason, which notice shall describe such
condition(s); (2) the Company fails to remedy such condition(s) within thirty (30) days following receipt of the written notice (the “Cure Period”); and (3) the Executive voluntarily resigns from employment with the
Company within thirty (30) days following the end of the Cure Period. 
 5.5 Effect of Termination. The Executive agrees
that should the Executive’s employment terminate for any reason, the Executive shall be deemed to have resigned from any and all positions with the Company, including, but not limited to, the Executive’s position on the Board and Parent
Board, as applicable. 
 5.6 Section 409A Compliance. 

(a) It is intended that any benefits under this Agreement satisfy, to the greatest extent possible, the exemptions from the application
of Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”), provided under Treasury Regulations Sections 1.409A-1(b)(4), and
1.409A-1(b)(9), and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt, this Agreement (and any definitions hereunder) will be
construed in a manner that complies with Section 409A. For purposes of Section 409A (including, without limitation, for purposes of Treasury Regulations Section 1.409A-2(b)(2)(iii)), the
Executive’s right to receive any installment payments under this Agreement (whether severance payments, if any, or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment
hereunder shall at all times be considered a separate and distinct payment. A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or
following a termination of employment unless such termination is also a “separation from service” within the meaning of Section 409A and, for purposes of any such provision of this Agreement, references to a “resignation,”
“termination,” “termination of employment” or like terms shall mean separation from service. In no event may Executive, directly or indirectly, designate the calendar year of a payment. Notwithstanding any provision of this
Agreement to the contrary, in no event shall the timing of the Executive’s execution of the Release, directly or indirectly, result in the Executive designating the calendar year of payment of any amounts of deferred compensation subject to
Section 409A, and if a payment that is subject to execution of the Release could be made in more than one taxable year, payment shall be made in the later taxable year. The Company makes no representation or warranty and shall have no liability
to the Executive or any other person if any compensation under this Agreement constitutes deferred compensation subject to Code Section 409A but does not satisfy an exemption from, or the conditions of, Code Section 409A. 

(b) Notwithstanding any provision to the contrary in this Agreement, if the Executive is deemed by the Company at the time of a
separation from service to be a “specified 

 EXECUTION VERSION 

 
 employee” for purposes of Section 409A(a)(2)(B)(i), and if any payments or
benefits that the Executive becomes entitled to under this Agreement on account of such separation from service are deemed to be “deferred compensation,” then to the extent delayed commencement of any portion of such payments or benefits
is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) and the related adverse taxation under Section 409A, such payments shall not be provided prior to the earliest of (i) the expiration of the six
(6)-month period measured from the date of separation from service, (ii) the date of the Executive’s death or (iii) such earlier date as permitted under Section 409A without the imposition of adverse taxation. Upon the first
(1st) business day following the expiration of such period, all payments deferred pursuant to this paragraph shall be paid in a lump sum, and any remaining payments due shall be paid as otherwise provided herein. No interest shall be due on any
amounts so deferred. 
 (c) With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by Section 409A, (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another
benefit, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year, and (iii) such payments shall be made on or before the last day of the Executive’s taxable year following the taxable year in which the expense
was incurred. 
 6. ARBITRATION. 

Except as otherwise set forth below in connection with equitable remedies, any dispute, claim or controversy arising out of or relating to this
Agreement or the Executive’s employment with the Company (collectively, “Disputes”), including, without limitation, any dispute, claim or controversy concerning the validity, enforceability, breach or termination of this
Agreement, if not resolved by the parties, shall be finally settled by arbitration in accordance with the then-prevailing Employment Arbitration Rules and Procedures of JAMS, as modified herein (“Rules”). The requirement to
arbitrate covers all Disputes (other than disputes which by statute are not arbitrable) including, but not limited to, claims, demands or actions under the Age Discrimination in Employment Act (including Older Workers Benefit Protection Act);
Americans with Disabilities Act; Civil Rights Act of 1866; Civil Rights Act of 1991; Employee Retirement Income Security Act of 1974; Equal Pay Act; Family and Medical Leave Act of 1993; Title VII of the Civil Rights Act of 1964; Fair Labor
Standards Act; Fair Employment and Housing Act; and any other law, ordinance or regulation regarding discrimination or harassment or any terms or conditions of employment. There shall be one arbitrator who shall be jointly selected by the parties.
If the parties have not jointly agreed upon an arbitrator within twenty (20) calendar days of respondent’s receipt of claimant’s notice of intention to arbitrate, either party may request JAMS to furnish the parties with a list of
names from which the parties shall jointly select an arbitrator. If the parties have not agreed upon an arbitrator within ten (10) calendar days of the transmittal date of such list, then each party shall have an additional five
(5) calendar days in which to strike any names objected to, number the remaining names in order of preference, and return the list to JAMS, which shall then select an arbitrator in accordance with the Rules. The

 EXECUTION VERSION 

 
 place of arbitration shall be New York, New York. By agreeing to arbitration, the
parties hereto do not intend to deprive any court of its jurisdiction to issue a pre-arbitral injunction, including, without limitation, with respect to the NDIA. The arbitration shall be governed by the
Federal Arbitration Act, 9 U.S.C. §§ 1-16. Judgment upon the award of the arbitrator may be entered in any court of competent jurisdiction. The arbitrator shall: (a) have authority to compel
discovery which shall be narrowly tailored to efficiently resolve the disputed issues in the proceeding; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to
each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based. The Company shall pay all administrative fees of JAMS in excess of four hundred thirty-five dollars ($435) (a typical
filing fee in court) but the Company and the Executive shall split any arbitrator’s fees and expenses. Each party shall bear its or his/her own costs and expenses (including attorney’s fees) in any such arbitration and the arbitrator shall
have no power to award costs and attorney’s fees except as provided by statute or by separate written agreement between the parties. In the event any portion of this arbitration provision is found unenforceable by a court of competent
jurisdiction, such portion shall become null and void leaving the remainder of this arbitration provision in full force and effect. The parties agree that all information regarding the arbitration, including any settlement thereof, shall not be
disclosed by the parties hereto, except as otherwise required by applicable law. 
 7. GENERAL PROVISIONS.

 7.1 Representations and Warranties. 

(a) The Executive represents and warrants that the Executive is not restricted or prohibited, contractually or otherwise, from
entering into and performing each of the terms and covenants contained in this Agreement, and that the Executive’s execution and performance of this Agreement will not violate or breach any other agreements between the Executive and any other
person or entity. The Executive represents and warrants that the Executive is not subject to any confidentiality or non-competition agreement or any other similar type of restriction that could restrict in any
way the Executive’s hiring by the Company and the performance of the Executive’s expected job duties with the Company. 
 (b)
The Company and its affiliates do not wish to incorporate any unlicensed or unauthorized material, or otherwise use such material in any way in connection with, its and their respective products and services. Therefore, the Executive hereby
represents, warrants and covenants that the Executive has not and will not disclose to the Company or its affiliates, use in their business, or cause them to use, any information or material which is a trade secret, or confidential or proprietary
information, of a third party, including, but not limited to, any former employer, competitor or client, unless the Company or its affiliates have a right to receive and use such information or material. 

(c) The Executive represents and warrants that the Executive is not debarred and has not received notice of any action or threat with
respect to debarment under the provisions of the Generic Drug Enforcement Act of 1992, 21 U.S.C. § 335(a) or any similar legislation applicable in the United States or in any other country where the Company intends to

 EXECUTION VERSION 

 
 develop its activities. The Executive understands and agrees that this Agreement is
contingent on the Executive’s submission of satisfactory proof of identity and legal authorization to work in the United States, as well as verification of auditor independence. 

7.2 Advertising Waiver. The Executive agrees to permit the Company, and persons or other organizations authorized by the Company, to
use, publish and distribute advertising or sales promotional literature concerning business of the Company in which the Executive’s name and/or pictures of the Executive appear. The Executive hereby waives and releases any claim or right the
Executive may otherwise have arising out of such use, publication or distribution. 
 7.3 Miscellaneous. 

(a) This Agreement, along with the NDIA and any applicable equity awards that have been granted, constitutes the complete, final and
exclusive embodiment of the entire agreement between the Executive and the Company with regard to its subject matter. It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein,
and it supersedes any other such promises, warranties or representations. 
 (b) This Agreement may not be modified or amended except
in a writing signed by both the Executive and a duly authorized officer or member of the Board. 
 (c) This Agreement will bind the
heirs, personal representatives, successors and assigns of both the Executive and the Company, and inure to the benefit of both the Executive and the Company, and to the Executive’s and the Company’s heirs, successors and assigns, as
applicable, except that the duties and responsibilities of the Executive are of a personal nature and shall not be assignable or delegable in whole or in part by the Executive. The Company may assign its rights, together with its obligations
hereunder, in connection with any merger, consolidation, or transfer or other disposition of all or substantially all of its assets, and such rights and obligations shall inure to, and be binding upon, any successor to the Company or any successor
to all or substantially all of the assets of the Company, which successor shall expressly assume such obligations. 
 (d) If any
provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement and the provision in question will be modified so as to be rendered enforceable.

 (e) This Agreement will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the
State of New York as applied to contracts made and to be performed entirely within New York. 
 (f) Any ambiguity in this Agreement
shall not be construed against either party as the drafter. Any waiver of a breach of this Agreement shall be in writing and shall 

 EXECUTION VERSION 

 
 not be deemed to be a waiver of any successive breach. This Agreement may be executed in
counterparts and facsimile signatures will suffice as original signatures. 
 [SIGNATURE PAGE FOLLOWS] 

 EXECUTION VERSION 

 
 IN WITNESS WHEREOF,
the parties have executed this Agreement as of the day and year first written above. 
  

			
	IMMUNOVANT, INC.
		
	By:	 	 /s/ Mayukh Sukhatme

		 	Name: Mayukh Sukhatme
		 	Title:   President, Roivant Pharma

  

	
	ACCEPTED AND AGREED:
	
	 /s/ Pete Salzmann

	Pete Salzmann
	
	May 30, 2019

 EXECUTION VERSION 

 
 EXHIBIT A: 

RELEASE FORM 

 EXECUTION VERSION 

 
 [DATE] 

Pete Salzmann 
 [ADDRESS] 

[CITY], [STATE] [ZIP] 
 RE: Separation
Agreement and General Release 
 Dear Pete, 

Your employment with Immunovant, Inc. will be terminated effective [DATE OF TERMINATION]. This Separation Agreement and General Release (this
“Agreement”) sets forth the terms and conditions under which Immunovant, Inc. is offering you additional pay and benefits in exchange for you making and honoring certain commitments, including agreeing not to pursue legal action against
the Company as described in Sections 7 and 8. 
 PLEASE NOTE: THIS DOCUMENT HAS IMPORTANT LEGAL CONSEQUENCES TO YOU. YOU SHOULD CONSULT AN
ATTORNEY OF YOUR CHOICE, AT YOUR EXPENSE, PRIOR TO EXECUTING IT. 
  

	1.	 Parties To This Agreement 

This letter is a proposed agreement that Immunovant, Inc. is offering to you. In this document, references to Pete Salzmann refer to
“you” and IMMUNOVANT, INC. is referred to as “Immunovant” or the “Company.” Together, you and Immunovant are referred to as the “Parties.” 

 

	2.	 What You Will Receive Regardless of Whether You Enter Into This Agreement 

Whether or not you enter into this Agreement, you will receive the following: 

 

	 	a.	 Your regular base pay (less applicable withholding) through [SEPARATION DATE], provided you remain employed at
the Company through that date. You will be receiving your regular pay in the same manner that you normally receive your regular pay, such as direct deposit, consistent with established bi-monthly pay cycles as
long as you remain employed; and 

  

	 	b.	 If you are currently enrolled and participating in the Company’s medical/dental/vision benefits, your
coverage will extend until the end of [SEPARATION MONTH] (the month in which your separation takes place). Thereafter, you will be able to continue as a member of the Company’s Group Health Plans at your expense in accordance with the terms of
those plans, as well as COBRA, for the legally required benefit continuation period. You will be receiving a separate letter explaining your rights and responsibilities with regard to electing your COBRA benefits; and 

 

	 	c.	 Accrued vested benefits under any applicable retirement plans offered by the Company. You will receive
information directly from Fidelity and you may direct questions to them at 1-800-603-4015; and 

 EXECUTION VERSION 

 
  

	 	d.	 Reimbursement for all approved business-related expenses incurred up to your last day of employment consistent
with established travel and expense policies; and 

  

	 	e.	 As long as you direct reference inquiries from potential employers to [Contact Name], Immunovant, Inc., [320
West 37th Street, 6th Floor, New York, NY 10018], unless otherwise authorized in writing, the Company will limit information it discloses in response to reference
requests to: (1) your dates of employment; and (2) your last position held. Of course, the Company reserves the right to respond truthfully to any compulsory process of law (such as a subpoena) or as otherwise required by law.

  

	3.	 What You Will Receive Only If You Enter Into This Agreement. 

As long as you timely sign, date and return this Agreement (BUT IN NO CASE LATER THAN [LAST DATE TO ACCEPT]), and you comply with
the Agreement’s requirements, then in addition to those payments and benefits described in Section 2 above: 
  

	 	•	 	 You will receive salary continuation benefit payments at your regular Base Salary though [SEVERANCE END DATE]
subject to applicable withholdings, unless you choose to resign before [SEPARATION DATE]; and 

  

	 	•	 	 If you are currently enrolled and participating in the Company’s medical/dental/vision benefits, your
coverage will extend until the end of the month in which your separation takes place [SEPARATION MONTH], unless you choose to resign before [FIRST DAY OF SEPARATION MONTH]. Thereafter, you will be able to continue as a member of the Company’s
Group Health Plans at your expense in accordance with the terms of those plans[, as well as COBRA, for the legally required benefit continuation period]. You will be receiving a separate letter explaining your rights and responsibilities with regard
to electing your COBRA benefits. 

 Within thirty (30) days after you return the signed and dated Agreement, you will
begin receiving the salary continuation benefit, provided you did not resign prior to your anticipated Separation Date. 
  

	4.	 W-2s. 

The Company will issue an IRS Form W-2 to you in connection with payments described in Section 3.

  

	5.	 How To Enter Into This Agreement. 

In order to enter into this Agreement, you must take the following steps: 

 

	 	a.	 You must sign and date the Agreement. Signing and dating the Agreement is how you “Execute” the
Agreement. 

  

	 	b.	 You must return the Executed Agreement to me before [LAST DATE TO ACCEPT], (unless such period is extended in
writing by the Company). If I do not receive the signed and dated Agreement by that date, the offer will be deemed withdrawn, this Agreement will not take effect and you will not receive the pay and benefits described in Section 3.

 EXECUTION VERSION 

 
  

	 	c.	 You must comply with the terms and conditions of this Agreement. 

 

	6.	 Your Acknowledgments. 

By entering into this Agreement, you are agreeing: 
  

	 	•	 	 The pay and benefits in Section 3 are more than any money or benefits that you are otherwise promised or
entitled to receive under any policy, plan, handbook or practice of the Company or any prior offer letter, agreement or understanding between the Company and you. 

 

	 	•	 	 After your employment ends, except as provided for in this Agreement (and without impacting any accrued vested
benefits under any applicable tax-qualified retirement or other benefit plans of the Company]), you will no longer participate or accrue service credit of any kind in any employee benefits plan of the Company
or any of its affiliates. 

  

	 	•	 	 Your obligations under your signed May [●], 2019 Letter of Employment Offer and Terms with the Company
(“Offer Letter”) (a copy of which is attached) and the Employee Non-Disclosure, Inventions Assignment and Restrictive Covenant Agreement (“NDIA”) executed between you and the Company on May
[●], 2019 (also attached), shall remain in full force and effect and you acknowledge and re-affirm those obligations. 

 

	 	•	 	 As long as the Company satisfies its obligation under the Agreement, it will not owe you anything except for the
items set forth in Section 2, which you will receive regardless of whether you Execute this Agreement. 

  

	 	•	 	 During your employment with the Company, you did not violate any federal, state, or local law, statute, or
regulation while acting within the scope of your employment with the Company (collectively, “Violations”). 

  

	 	•	 	 You are not aware of any Violation(s) committed by a Company employee, vendor, or customer acting within the
scope of his/her/its employment or business with the Company that have not been previously reported to the Company; or (ii) to the extent you are aware of any such unreported Violation(s), you will, prior to your execution of this Agreement,
immediately report such Violation(s) to the Company. 

  

	7.	 YOU ARE RELEASING AND WAIVING CLAIMS 

While it is very important that you read this entire Agreement carefully, it is especially important that you read this Section
carefully, because it lists important rights you are giving up if you decide to enter into this Agreement. 

 EXECUTION VERSION 

 
 What Are You Giving Up? It is the Company’s position
that you have no legitimate basis for bringing a legal action against it. You may agree or believe otherwise or simply not know. However, if you Execute this Agreement, you will, except for certain exceptions described in Section 11, give up
your ability to bring a legal action against the Company and others, including, but not limited to its affiliates. More specifically, by Executing this Agreement, you will give up any right you may have to bring various types of “Claims,”
which means possible lawsuits, claims, demands and causes of action of any kind (based on any legal or equitable theory, whether contractual, common-law, statutory, federal, state, local or otherwise), whether
known or unknown, by reason of any act or omission up to and including the date on which you Execute this Agreement. You are also giving up potential Claims arising under any contract or implied contract, including but not limited to your Employment
Offer and Terms letter or any handbook, tort law or public policy having any bearing on your employment or the termination of your employment, such as Claims for wrongful discharge, discrimination, hostile work environment, breach of contract,
tortious interference, harassment, bullying, infliction of emotional distress, defamation, back pay, vacation pay, sick pay, wage, commission or bonus payment, equity grants, stock options, restricted stock option payments, payments under any bonus
or incentive plan, attorneys’ fees, costs and future wage loss. This Agreement includes a release of your right to assert a Claim of discrimination on the basis of age, sex, race, religion, national origin, marital status, sexual orientation,
gender identity, gender expression, ancestry, parental status, handicap, disability, military status, veteran status, harassment, retaliation or attainment of benefit plan rights. However, as described in Section 11, this Agreement does not and
cannot prevent you from asserting your right to bring a claim against the Company and Releasees, as defined below, before the Equal Employment Opportunity Commission or other agencies enforcing non-discrimination laws or the National Labor Relations
Board. 
 Whose Possible Claims Are You Giving Up? You are waiving Claims that you may otherwise be able to bring. You are not
only agreeing that you will not personally bring these Claims in the future, but that no one else will bring them in your place, such as your heirs and executors, and your dependents, legal representatives and assigns. Together, you and these groups
of individuals are referred to in the Agreement as “Releasors.” 
 Who Are You Releasing From Possible Claims? You
are not only waiving Claims that you and the Releasors may otherwise be able to bring against the Company, but also Claims that could be brought against “Releasees,” which means the Company and all of their past, present and future: 

 

	 	•	 	 shareholders 

  

	 	•	 	 officers, directors, employees, attorneys and agents 

 

	 	•	 	 subsidiaries, divisions and affiliated and related entities 

 

	 	•	 	 employee benefit and pension plans or funds 

 

	 	•	 	 successors and assigns 

 

	 	•	 	 trustees, fiduciaries and administrators 

 EXECUTION VERSION 

 
 Possible Claims You May Not Know. It is possible that you
may have a Claim that you do not know exists. By entering into this Agreement, you are giving up all Claims that you ever had including Claims arising out of your employment or the termination of your employment. Even if Claims exist that you do not
know about, you are giving them up. 
 What Types of Claims Are You Giving Up? In exchange for the pay and benefits in
Section 3, you (on behalf of yourself and the Releasors) forever release and discharge the Company and all of the Releasees from any and all Claims including Claims arising under the following laws (including amendments to these laws): 

Federal Laws, such as: 
  

	 	•	 	 Title VII of the Civil Rights of 1964; 

 

	 	•	 	 Sections 1981 through 1988 of Title 42 of the United States Code; 

 

	 	•	 	 The Civil Rights Act of 1991; 

 

	 	•	 	 The Equal Pay Act; 

  

	 	•	 	 The Americans with Disabilities Act; 

 

	 	•	 	 The Rehabilitation Act; 

 

	 	•	 	 The Employee Retirement Income Security Act; 

 

	 	•	 	 The Worker Adjustment and Retraining Notification Act; 

 

	 	•	 	 The National Labor Relations Act; 

 

	 	•	 	 The Fair Credit Reporting Act; 

 

	 	•	 	 The Occupational Safety and Health Act; 

 

	 	•	 	 The Uniformed Services Employment and Reemployment Act; 

 

	 	•	 	 The Employee Polygraph Protection Act; 

 

	 	•	 	 The Immigration Reform Control Act; 

 

	 	•	 	 The Family and Medical Leave Act; 

 

	 	•	 	 The Genetic Information Nondiscrimination Act; 

 

	 	•	 	 The Federal False Claims Act; 

 

	 	•	 	 The Patient Protection and Affordable Care Act; 

 

	 	•	 	 The Consolidated Omnibus Budget Reconciliation Act; and 

 

	 	•	 	 The Lilly Ledbetter Fair Pay Act. 

State and Municipal Laws, such as: 
  

	 	•	 	 The New York State Human Rights Law; the New York State Executive Law; the New York State Civil Rights Law; the
New York State Whistleblower Law; the New York State Legal Recreational Activities Law; the retaliation provisions of the New York State Workers’ Compensation Law; the New York Labor Law; the New York State Worker Adjustment and Retraining
Notification Act; the New York State False Claims Act; New York State Wage and Hour Laws; the New York State Equal Pay Law; the New York State Rights of Persons with Disabilities Law; the New York State Nondiscrimination Against Genetic Disorders
Law; the New York State Smokers’ Rights Law; the New York AIDS Testing Confidentiality Act; the New 

 EXECUTION VERSION 

 

	 	York Genetic Testing Confidentiality Law; the New York Discrimination by Employment Agencies Law; the New York Bone Marrow Leave Law; the New York Adoptive Parents Child Care Leave Law; the New York City Human Rights Law; the New
York City Administrative Code; the New York City Paid Sick Leave Law; and the New York City Charter; and 

  

	 	•	 	 [IF EMPLOYEE WAS EVER EMPLOYED IN NJ] The New Jersey Law Against Discrimination; the New Jersey Discrimination in
Wages Law; the New Jersey Security and Financial Empowerment Act; the New Jersey Temporary Disability Benefits and Family Leave Insurance Law; the New Jersey Domestic Partnership Act; the New Jersey Conscientious Employee Protection Act; the New
Jersey Family Leave Act; the New Jersey Wage Payment Act; the New Jersey Equal Pay Law; the New Jersey Occupational Safety and Health Law; the New Jersey False Claims Act; the New Jersey Smokers’ Rights Law; the New Jersey Genetic Privacy Act;
the New Jersey Fair Credit Reporting Act; the New Jersey Emergency Responder Leave Law; the New Jersey Millville Dallas Airmotive Plant Job Loss Notification Act (a/k/a the New Jersey WARN Act); and the retaliation provisions of the New Jersey
Workers’ Compensation Law; and 

  

	 	•	 	 [IF EMPLOYEE WAS EVER EMPLOYED IN CA] The California Fair Employment and Housing Act, as amended; the California
Constitution, as amended; the California Labor Code, as amended; and all rights under Section 1542 of the California Civil Code, which states, “A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO
EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.” You acknowledge that you may later discover claims or facts in addition to or
different from those which you now know or believe to exist with regards to the subject matter of this Agreement, and which, if known or suspected at the time of executing this Agreement, may have materially affected its terms. Nevertheless, you
waive any and all Claims that might arise as a result of such different or additional claims or facts; and 

  

	 	•	 	 [IF EMPLOYEE WAS EVER EMPLOYED IN NC] The North Carolina Employment Practices Act; the Retaliatory Employment
Discrimination Act; the Persons with Disabilities Protection, Discrimination Against Persons with Sickle Cell Trait; Discrimination Based Upon Genetic Testing and Information; Discrimination Based Upon Use of Lawful Products; Discrimination Based
Upon AIDS or HIV Status; Hazardous Chemicals Right to Know Act; Jury Service Discrimination; Military Service Discrimination; and all of their respective implementing regulations; and 

 

	 	•	 	 [IF EMPLOYEE WAS EVER EMPLOYED IN MA] The Massachusetts Fair Employment

 EXECUTION VERSION 

 

	 	Practices Law; the Massachusetts Civil Rights Act; the Massachusetts Equal Rights Act; the Minimum Fair Wage Act; the Massachusetts Plant Closing Law; the Massachusetts Equal Pay Act; the Massachusetts Parental Leave Act; the
Massachusetts Sexual Harassment Statute; and all of their respective implementing regulations. By signing this letter agreement, you are acknowledging that this waiver includes any future claims against the Company under Mass. Gen. Laws ch. 149,
§ 148—the Massachusetts Wage Act. These claims include, but are not limited to, failure to pay earned wages, failure to pay overtime, failure to pay earned commissions, failure to timely pay wages, failure to pay accrued vacation or
holiday pay, failure to furnish appropriate pay stubs, claims for improper wage deductions, and claims for failing to provide proper check-cashing facilities. 

You Are Giving Up Potential Remedies and Relief. You are waiving any relief that may be available to you (such as money damages, equity grants,
benefits, attorneys’ fees, and equitable relief such as reinstatement) under any of the waived Claims, except as provided in Section 11. 

This Release Is Extremely Broad. This release is meant to be as broad as legally permissible and applies to both employment-related and non-employment-related Claims up to the time that you execute this Agreement. This release includes a waiver of jury trials and non-jury trials. This Agreement does not
release or waive Claims or rights that, as a matter of law, cannot be waived, which include, but are not necessarily limited to, the exceptions to your release of claims or covenant not to sue referenced in Section 11. 

 

	8.	 YOU ARE AGREEING NOT TO SUE 

Except as provided in Section 11, you agree not to sue or otherwise bring any legal action against the Company or any of the Releasees
ever for any Claim released in Section 6 arising before you Execute this Agreement. You are not only waiving any right you may have to proceed individually, but also as a member of a class or collective action. You waive any and all rights you
may have had to receive notice of any class or collective action against Releases for claims arising before you Execute this Agreement. In the event that you receive notice of a class or collective action against Releasees for claims arising before
you Execute this Agreement, you must “opt out” of and may not “opt in” to such action. You are also giving up any right you may have to recover any relief, including money damages, from the Releasees as a member of a class or
collective action. 
  

	9.	 Representations Under The FMLA (leave law) And FLSA (wage and hour law). 

You represent that you are not aware of any facts that might justify a Claim by you against the Company for any violation of the Family and
Medical Leave Act (“FMLA”). You also represent that you have received all wages for all work you performed and any commissions, bonuses, stock options, restricted stock option payments, overtime compensation and FMLA leave to which you may
have been entitled, and that you are not aware of any facts constituting a violation by the Company or Releasees of any violation of the Fair Labor Standards Act or any other federal, state or municipal laws. 

 EXECUTION VERSION 

 

	10.	 You Have Not Already Filed An Action. 

You represent that you have not sued or otherwise filed any actions (or participated in any actions) of any kind against the Company or
Releasees in any court or before any administrative or investigative body or agency. The Company is relying on this assurance in entering into this Agreement. 
  

	11.	 Exceptions To Your Release Of Claims And Covenant Not To Sue 

In Sections 7 and 8, you are releasing Claims and agreeing not to sue, but there are exceptions to those commitments. Specifically, nothing in
this Agreement prevents you from bringing a legal action or otherwise taking steps to: 
  

	 	•	 	 Enforce the terms of this Agreement; or 

 

	 	•	 	 Challenge the validity of this Agreement; or 

 

	 	•	 	 Make any disclosure of information required by law; or 

 

	 	•	 	 Provide information to, testify before or otherwise assist in any investigation or proceeding brought by, any
regulatory or law enforcement agency or legislative body, any self-regulatory organization, or the Company; or 

  

	 	•	 	 Provide truthful testimony in any forum; or 

 

	 	•	 	 Cooperate fully and provide information as requested in any investigation by a governmental agency or commission;
or 

  

	 	•	 	 File a charge or complaint with the Equal Employment Opportunity Commission, the National Labor Relations Board,
the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (“Government Agencies”); or 

 

	 	•	 	 File a lawsuit or other action to pursue Claims that arise after you Execute this Agreement.

 For purposes of clarity, this Agreement does not limit your ability to communicate with any Government Agencies or
otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. This Agreement does not limit your right to receive an award
for information provided to any Government Agencies. 
  

	12.	 Your Continuing Obligations. 

You acknowledge and re-affirm your continuing obligations pursuant to the Offer Letter and the NDIA
executed between you and the Company, including your confidentiality obligations under Section 2 of the NDIA and any restrictions under Sections 4 and 5 of the NDIA. 

Pursuant to the Defend Trade Secrets Act of 2016, you acknowledge and understand that you will not be held criminally or civilly liable under
any federal or state trade secret law for the disclosure of the trade secrets of the Company or any of its affiliates that is made by you (i) in confidence to 

 EXECUTION VERSION 

 
 a federal, state, or local government official, either directly or
indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law, or (ii) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. 

 

	13.	 Return Of Property. 

As of your Separation Date, you agree that you have returned to the Company all property belonging to the Company including, but not limited
to, electronic devices, equipment, access cards, and paper and electronic documents obtained in the course of your employment. 
  

	14.	 Prior Disclosures. 

You acknowledge that, prior to the termination of your employment with the Company, you disclosed to the Company, in accordance with applicable
policies and procedures, any and all information relevant to any investigation of the Company’s business practices conducted by any governmental agency or to any existing, threatened or anticipated litigation involving the Company, whether
administrative, civil or criminal in nature, and that you are otherwise unaware of any wrongdoing committed by any current or former employee of the Company that has not been disclosed. Nothing in this Agreement shall prohibit or restrict you or the
Company from (1) making any disclosure of information required by law; (2) providing information to, or testifying or otherwise assisting in any investigation or proceeding brought by any federal or state regulatory or law enforcement
agency or legislative body, any self-regulatory organization, or with respect to any internal investigation by the Company or its affiliates; or (3) testifying, participating in or otherwise assisting in a proceeding relating to an alleged
violation of the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, any federal, state or municipal law relating to fraud, or any rule or regulation of any self-regulatory organization. 

 

	15.	 Non-Disparagement 

You agree that you will not, through any medium including, but not limited to, the press, Internet or any other form of communication,
disparage, defame, or otherwise damage or assail the reputation, integrity or professionalism of the Company or the Releasees. Nothing in this Section 15 is intended to restrict or impede your participation in proceedings or investigations
brought by or before the EEOC, NLRB, or other federal, state or local government agencies, or otherwise exercising protected rights to the extent that such rights cannot be waived by agreement, including Section 7 rights under the National
Labor Relations Act. 
  

	16.	 The Company’s Remedies For Breach. 

If you breach any section of this Agreement, including without limitation, Section 7, 8, or 15 or otherwise seek to bring a Claim given up
under this Agreement, the Company will be entitled to all relief legally available to it including equitable relief such as injunctions, and the Company will not be required to post a bond. 

 EXECUTION VERSION 

 
 You further acknowledge that if you breach of any section of this
Agreement, you will automatically forfeit your right to receive any of the benefits enumerated in Section 3 of this agreement. 
 You
further acknowledge and understand that if the Company should discover any such Violation(s) as described in Section 6 after your execution of this Agreement and/or your separation from employment with the Company, it will be considered a
material breach of this Agreement, and all of the Company’s obligations to you hereunder will become immediately null and void. 
  

	17.	 Governing Law. 

This Agreement is governed by New York law, without regard to conflicts of laws principles. 

 

	18.	 Successors And Assigns. 

This Agreement is binding on the Parties and their heirs, executors, successors and assigns. 

 

	19.	 Severability And Construction. 

If a court with jurisdiction to consider this Agreement determines that any provision is illegal, void or unenforceable, that provision will be
invalid. However, the rest of the Agreement will remain in full force and effect. A court with jurisdiction to consider this Agreement may modify invalid provisions if necessary to achieve the intent of the Parties. 

 

	20.	 No Admission. 

By entering into this Agreement, neither you nor the Company admits wrongdoing of any kind. 

 

	21.	 Do Not Rely On Verbal Statements. 

 

	 	•	 	 This Agreement sets forth the complete understanding between the Parties. 

 

	 	•	 	 This Agreement may not be changed orally. 

 

	 	•	 	 This Agreement constitutes and contains the complete understanding of the Parties with regard to the end of your
employment, and supersedes and replaces all prior oral and written agreements and promises between the Parties, except that, as set forth in Section 6, your restrictive covenant obligations remain in full force and effect.

  

	 	•	 	 Neither the Company nor any representative (nor any representative of any other company affiliated with the
Company), has made any promises to you other than as written in this Agreement. All future promises and agreements must be in writing and signed by both Parties. 

 EXECUTION VERSION 

 

	22.	 Your Opportunity To Review. 

 

	 	a.	 Review Period. You have twenty-one
(21) calendar days from the day you receive this Agreement to consider the terms of this Agreement, sign it and return it to [Contact Name], Immunovant, Inc., [320 West
37th Street, 6th Floor, New York, NY 10018]. Your opportunity to accept the terms of this Agreement will expire at the conclusion of the
twenty-one (21) calendar day period if you do not accept those terms before time expires. That means that your opportunity to accept the terms of this Agreement will expire on [LAST DATE TO ACCEPT]. You
may sign the Agreement in fewer than twenty-one (21) calendar days, if you wish to do so. If you elect to do so, you acknowledge that you have done so voluntarily. Your signature below indicates that
you are entering into this Agreement freely, knowingly and voluntarily, with full understanding of its terms. 

  

	 	b.	 Talk To A Lawyer. During the review period, and before executing this Agreement, the Company
advises you to consult with an attorney, at your own expense, regarding the terms of this Agreement. 

  

	23.	 We Want To Make Absolutely Certain That You Understand This Agreement. 

You acknowledge and agree that: 
  

	 	•	 	 You have carefully read this Agreement in its entirety; 

 

	 	•	 	 You have had an opportunity to consider the terms of this Agreement; 

 

	 	•	 	 You understand that the Company urges you to consult with an attorney of your choosing, at your expense,
regarding this Agreement; 

  

	 	•	 	 You have the opportunity to discuss this Agreement with a lawyer of your choosing, and agree that you had a
reasonable opportunity to do so, and he or she has answered to your satisfaction any questions you asked with regard to the meaning and significance of any of the provisions of this Agreement; 

 

	 	•	 	 You fully understand the significance of all of the terms and conditions of this Agreement; and

  

	 	•	 	 You are Executing this Agreement voluntarily and of your own free will and agree to all the terms and
conditions contained in this Agreement. 

 EXECUTION VERSION 

 

									
	  
 IMMUNOVANT,
INC.
	 		 	  
 PETE
SALZMANN

									
					
	By:	 	  
	 		 		 	
		 		 		 		 	
	Dated:	 	  
	 		 	Dated:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}]]